



US007671187B2

(12) **United States Patent**
Aguirre et al.

(10) **Patent No.:** **US 7,671,187 B2**
(45) **Date of Patent:** **Mar. 2, 2010**

(54) **IDENTIFICATION OF THE GENE AND MUTATION RESPONSIBLE FOR PROGRESSIVE ROD-CONE DEGENERATION IN DOG AND A METHOD FOR TESTING SAME**

(75) Inventors: **Gustavo Aguirre**, Philadelphia, PA (US); **Gregory M. Acland**, Kennett Square, PA (US); **Barbara Zangerl**, Philadelphia, PA (US); **Orly Goldstein**, Ithaca, NY (US); **Susan Pearce-Kelling**, Berkshire, NY (US); **Jeanette S. Felix**, Horseheads, NY (US); **Duska J. Sidjanin**, Brookfield, WI (US)

(73) Assignee: **Cornell Research Foundation, Inc.**, Ithaca, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 276 days.

(21) Appl. No.: **11/983,870**

(22) Filed: **Nov. 13, 2007**

(65) **Prior Publication Data**
US 2009/0111976 A1 Apr. 30, 2009

Related U.S. Application Data
(62) Division of application No. 11/157,743, filed on Jun. 21, 2005, now Pat. No. 7,312,037.
(60) Provisional application No. 60/581,499, filed on Jun. 21, 2004.

(51) **Int. Cl.**
C07H 21/04 (2006.01)
C12Q 1/68 (2006.01)

(52) **U.S. Cl.** **536/23.1; 536/24.3**

(58) **Field of Classification Search** None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,804,388 A 9/1998 Aguirre et al.

FOREIGN PATENT DOCUMENTS

WO 9902731 A1 1/1999
WO 0029615 A2 5/2000

OTHER PUBLICATIONS

Acland et al.; A Novel Retinal Degeneration Locus Identified by Linkage and Comparative Mapping of Canine Early Retinal Degeneration; *Genomics*, 1999, vol. 59; pp. 134-142.

Caase et al.; A Gene Potentially Involved in Progressive Rod—Cone Degeneration (PRCD); Annual Meeting of the Association for Research in Vision and Ophthalmology, May 2003, Abstract No. 2318, vol. 2003; Biosis Online Biosciences Information Service; 2 pages.

Sargan et al.; Use of Flow-Sorted Canine Chromosomes in the Assignment of Canine Linkage, Radiation Hybrid, and Syntenic Groups to Chromosomes: Refinement and Verification of the Comparative Chromosome Map for Dog and Human; *Genomics*, Oct. 15, 2000, vol. 69, No. 2; pp. 182-195.

Sidjanin et al.; Radiation hybrid map, physical map, and low-pass genomic sequence of the canine prcd region on CFA9 and comparative mapping with the syntenic region on human chromosome 17; *Genomics*, 2003, vol. 81; pp. 138-148.

Primary Examiner—Jeanine A Goldberg
(74) *Attorney, Agent, or Firm*—Hodgson Russ LLP

(57) **ABSTRACT**

Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1.

2 Claims, 11 Drawing Sheets

```

1  CGGCCAGGTG GCACCTCTGA CTCCCAGCCC AACCTGATG CCAGTGTCCA
51  CTTCTCCCTG TCGCTCCCTC GCGACCCCGC CCTTCTCAAG ACTTGGTGTC
101 CCTCTGCAAG TGTGAGAAGA GGTCGGCTCA CCTCTTCCGC TTTGGCTTAT
151 GTATTTTAAA AATCGTTTTT CAAAGTAGAG AGCCCAGGTG CAGCCCCAGC
201 TCTGGCCCTC CCTGGGAGCC TGGGCAGGAG ACCCCTTGAC ACCGCTTCCA
251 TCTCCTTGGA GGAAGGAAA ATCTAGTGCA GACCYCTGGG GTTTTTGGAG
301 AGGGCTGGAG GAAGCTGGAT GCTCAGACCC CTGTGTGCTC CACATGCTGC
351 CTGGGCCACC TCACTGAACC CCTCTGACAG GACACCCGAT GCCTGTGCGG
401 TGCCCTTCCA AGTGGCTGCT CAGAAGCTTT GCACTGGGAA AGCAAGTATT
451 CGCTATTTCT ATTTAGTATT TCTATTTAGC TTTATCTCAT CTTTTACAAG
501 TCTTATGTGT GTTTATTATG CAGGACTGTA TTCGCACAGA TGTGGAAGAT
551 CTAATGTATG AGCAGATGCA TATACTTATT TCATGAGTGC AACTTAAAT
601 CCAGTCTTTT ATGGAAGGGG CTATGGAAAT CAGTAACATT TGGGGAGGAC
651 TGTCAGAGG GGAGAACACA ACTGCTCAGC CGCCCCTCCA CTCCCCGGCC
701 TCCCTTGTCT TTCTGGCTTC ATTATCTAAT ATTCTTCCTC CCCTCCCCAT
751 GGCTCTCCAT GACATCATTG TTCTGCCAAC ACTCAACTTC CAGTTGCTGG
801 AACATGCTCT GTGCTTTTGT GTCAGCCGCC CCGGAAGAGT CTTCTGTTGG
851 SGGGGAGGTA ACCTTCCTTG AACACCTGCA AATCCAATG CCCCAGCTC
901 CTCTCCCAAG CATTCCCTGA CACATGCAAC TCCGAAAGTG CTCTGCGGGT
951 GCCTCTCATC ACCCAAGTCG CTCTACTGTG GTCATTAATG TGACTTGCYA
1001 GCTCAAGTGT CTAGACTAGA AGCCCCTTGA GGGTTAGGCC CAGGTCCTAG
1051 TCACATCTGT ATCCAGAATG GACAGCTTGA TTTACCCTGC CACCGCAGGC
1101 GACAACCTGG GCCCAGTGAG GTTAATCAGT CTGCACAAGG TCGGGTTGGC
1151 TGACCCCACT AATCAGCTTG AGCCTCTAAT TCCAGTGGCA GCAGGAACCT
1201 CAGGATGGGC AGCAGTGGCT TGTGAGAGCC GGCAGGGCCA TTTTGGCCTT
1251 TCTCCTGCAG ACTCTGTCCG GGAGGGGATG GGCAGCTGA GCCATGTRCA
1301 CCACCCTCTT CCTACTCAGC ACCTTGGCCA TGCTCTGGCG CCGCCGGTTC
1351 GCCAACCGGG TCCAACCgtg agaagctgat ggggccatgg gcagggatgg
1401 ggagagagga gaagctaggg ggtgaggggt ggtgcagggg ctgcctggac
1451 ctctgggag gctggagggc ggggaggatt tgcagggagg tccagagagg
1501 tttcccatca gagcacgcg gggcgggggc tgcaggtgc tccgagactg
1551 gctggagtcc ccggtcccc agcccaacac ggccaggaga gggggttctg
1601 ggcccgggcg ctgcccacag ctcttccage ctcttctcc cggccacagG
1651 GAGCCAGCG GAGCAGACGG GGCAGTCGTG GGCAGCAGGT CCGAGAGAGA
1701 CCTCCAGTCC TCGGGCAGgt aaggcagagt ctgggctggg ggaggcaggg
1751 tgcgtcgagg aagcggctgc cctggccgcc ccgaccgtgc ctgggcaggt
1801 acatgagtgc acccgagccg gcgcgcccgg gcccctcgcc ccagccacc
1851 ggtcccgtg tgcccgggtg gcagcctcgg tgtctgtgct ccccgcggc
1901 actgggcgcc csggcctgtc ctctgcaccg cagctgctct gctttgcccg
1951 agtgccgggt ggtcccccg gtcccatcgg aaggcgcggg gggaccggag
2001 aggatggggc aggagcagct ccgggcccgc ggctcgctgc ccttccccct
2051 ccccgcggcc ccgctccgc ctccagcct cccctgcccc ggccgcccgc
2101 gggattcgcc caccggcccc caataggagg cgcaggagcg gcatgacgtc
2151 atcggcaccg cctgccattg gctgggcagc tcctgcgggc aggtcgctgt
2201 ctccagcggc cgaaagttaa ctcttcccta ggccgaagcc atgtggctcc
2251 acaagggggg aagtgtgggg aacttctgga ttcttcttc cctgggtgac
2301 cagtgtcctt tgatgttagg ggctcctatg cccaacaac cacggaaaaa

```

Figure 1A

2351	tcaacatgca	tttattaaga	acataaccgtt	gtgcgtgttc	ttttgtgccc
2401	ccggacccac	ctrgtggggg	agtcctgtgt	gaagggacat	tctctcctgc
2451	aaaaggtcta	ctagccttct	ctcaactcta	gtgagacaaa	gcacatgatg
2501	cccttgggct	ccggggcctg	tggttgagg	gagtctcccc	acagcgtca
2551	gatggctgag	ccagtgagcg	tgctgcctg	ctggggcacy	ccaccggctc
2601	<u>tcctccrggt</u>	gtgtaggacc	tgctgggtg	cccctcagcc	atgtggagac
2651	<u>tggcgagcca</u>	<u>tgagaaatga</u>	gaatgggaat	ctgtctccgt	atgcccggccc
2701	aaattcctcy	tcgggtgctgg	gattcctcca	agctctgaat	rtcaggaggg
2751	cagccctggg	catgtgccyg	agacaggtat	ttctgggcca	cccttccttg
2801	acaatctagg	ctagctgaga	tggtcatgat	actaccaag	taggcctgct
2851	ggtgaaatgg	gctgacaaag	gtgaaatgat	gagcactggg	cctcacgcag
2901	agcaggccct	tgaatgacta	gtcctccctg	ttgagtttg	gtctggaggc
2951	ggacagccag	agtcacatc	ctgactccct	gcttctgac	cgagagcctc
3001	tgggaaagct	atgtgatctt	tctatttgta	tataaactgg	gattaataac
3051	agaatggtgt	gggggtggtt	gtgaggttca	aattgagatc	atcctaaagc
3101	acttggcacg	aaacagctrt	ttaataaatg	ccggctagct	attctcctgt
3151	tgttacctgg	ctcttgatca	gtgttctatt	cttcccttga	ggtctcttaa
3201	acgttaactc	acttggaggt	tgtaacagcc	ccagaggggt	ggcaagacaa
3251	gtgtttctat	ctcttgtaa	tggtggagga	aactgagggg	aggggagggc
3301	tcagtttttc	actcgaggtc	atccatccta	tttgtggctg	atggcaactg
3351	acttcaggta	gtcggctctcc	tctacatgaa	atgggcctgg	accctccctg
3401	tcaggagaaa	aaagctgaat	ctggaccatc	tggcccagcc	tcgtggggtc
3451	tagccagaag	gaagcagttg	cctgttaact	cccagggacc	cagttaactg
3501	gaaaaatcag	cctaacatcc	aacacctcct	gcttcgggtg	gctgttgtga
3551	agggctggtc	tggggagcag	taggcatgac	atctctgctc	tgcaattcca
3601	cagtcacaaa	ttccagctga	ttcctgggt	gctcctacc	ctcagtagtg
3651	gggtgcctcc	ctaggcgtgg	ggcaaagggg	agaagtctgg	aaagacggga
3701	aggacgtccc	cttcaatcct	ctgactocca	tgcttttctg	tttag AAAGG
3751	AAGAGCCTCT	GAAG <u>TAA</u> GTC	TTCACCCGGT	CAGGCGGAGC	TCGGCCCCAG
3801	GGAYTGGGAT	CAGCTGGCAG	AGGCAG gtag	ggcagggctg	caagccttgg
3851	aaggtagagg	gctgggctgg	ggacaaggca	ggctctgcaa	ggcctggcca
3901	tgagggagca	gagctccatg	gagggtagac	agaaggcggg	tggcctctca
3951	tcagctcctg	cctcaagcct	setgtgggtcc	aggccatggc	gcaaggcttt
4001	gtagtthtta	agggaaagggc	gtgtgggtgaa	gtgggtggca	tgctggcact
4051	gtagtgccag	aggacttcta	agggagaggg	tgtgctctgg	aatatccatt
4101	ctgcaatgca	agccctgccc	ttgggatggg	aggaagtgcc	aatctggttt
4151	tctatttcag	TTCAAGTCCC	GGCTGGCCTC	TTACCCACAA	AGCATGCTGT
4201	GGTGGAAAGCA	GCAGCAGCAG	CAAGAAGAAA	AATGGGAAAA	AGCAGTCATC
4251	AAGAAGGTAG	ACTCCTCCCT	TTGAGTCCCT	GGACCTGCCT	GGCCTCCCTT
4301	TGCCCCAGAC	CCTGGTGGTG	GGGCTCCTGA	AGCAAGGCCT	GGCTGGGGCA
4351	GGCTGGAGGG	CAAAGACGCT	CATTGCCCTG	GCTTGGGCTC	CCTTCCTCTG
4401	AGATCCTGAG	GATAGTCTGA	GGCAGGCCCA	GAGAGGGACT	CAGGTTTCTT
4451	ATGGAAGGRC	TTCTCATTCA	TCCC <u>TAATAT</u>	<u>AAT</u> CCTTGCA	ATGACCCAAG
4501	AAGACTGGGC	GTGTTATTAT	CCACACTTTT	GGAAATGAGG	AAACAGAGAG
4551	AGGTTAAGGA	ATCTGTCCAG	TGTCATCCAG	CTAGTTAATC	CTGCCCCCA
4601	CCCCACCCA	CCCCCGCCC	TCCCAGCCTC	CTTTGGAGGC	TGCAGAGCCC

Figure 1B

4651	ACACTCTTAC	CCACCAGGGC	ACAGGCCTCT	CTGAAATCAC	CTGGAAGTTT
4701	GCAGCTTGCA	GCTGCTATGT	GAGAGCAGGG	GTTCCACGGG	CCCGGCAGCC
4751	CCAAAGCCTG	TGGTCCAAGG	CTGTGTGGTA	TCAGTTTGCC	ATGGTGGCGC
4801	TCTAGTTTCC	AGGGCACTTG	CCTCTCCCCG	GTCCCCAGAG	CTCACCCCGT
4851	CACCAGCCAC	TCTGCTGCAG	TTCTCAATAA	GAAATGCCAG	CTGGGATCTG
4901	TGACATGTCT	GCCTGCGGCT	GGAAGGAAGC	ATCTCTCAAC	CTGTCCTCTG
4951	AGCGTGTCTG	CGTGCCTGTG	TGCATGCGTG	CGTGTGTTCC	AAAGGGGCAG
5001	TCGCATGTGG	GAAGGGAAGA	AGCCTGACAC	TTGTTCTTGT	CAATCTGCTG
5051	ACTGCTCAGT	ACCACGGCGG	CTCTGCCATT	TCTCCCTCAC	AGTCCTGCTC
5101	GACCCAGAGC	AGAGATCAAA	GCAGATTTCC	GCTTCTGCTC	CCTGAGATCC
5151	AGGCGCAGAC	CTGCAGGCAG	CTGCTCCCCA	CTGTCTGGAA	GCCATTCATC
5201	ATGCAAAGCG	CCTCCCCACC	AAACCCCTGC	CTGCACGTGC	ATCRTCCCCC
5251	CACCATCACC	ATCCAGCCCC	CAGGGTGGGC	AGGGAGGTCC	CTGCCTAGCT
5301	GCACACCCCC	CAGGCCATCA	AGAGGCAGGA	GATGGGGAGT	TCTCTCGACA
5351	GCAGCCTGTC	TGCCGCCCTG	ACTCCACATC	TGAGGGAAGG	AAGGAAAGGG
5401	TGAGATGCCA	CAGACAGAGG	GGACCACGCT	GAAGCCATGG	GGGAGGGGCT
5451	GCTGATCTTG	CCCTGGAAGC	CTCTAGAAGT	AGGGCAGGGT	GGAGGCAGGG
5501	GAAGGGTCAA	ACCAGGGGAA	GGAGCTGTGC	GCTGGAATGG	CGACAGAGCC
5551	CCACCGCCCA	CTCGACATGG	GCCAGGAGTT	CGTGACCACC	TGTCTCAGCT
5601	CCTGTCAGCC	TGTCTTTCTC	CTGCGAGGTG	TTGGCCTTCC	TTGGTGACAG
5651	GGCTGTCCGG	CTGAGGGCCA	GGGGCACCGT	TCCTGGGGCC	CCCATCTKCG
5701	TCCCCGAGCC	CACCTGTGTA	TTCATCCTCT	AATCTGTTTG	CCATGCTCCT
5751	GTCACTTCAG	CCTCGGCTCT	GCTCTCTACC	ATTTCCACGT	TGCCTGCCTC
5801	CTTGCACTAG	TCTGAGGAAT	TGTCAGGCCA	AGGTCACCTG	GCTGGACAGG
5851	GGCTGGCCCA	CGGCCCAGAC	ACACCTCCAC	GAGGCGACAC	CCCTTCGCTG
5901	CACTGTTCTA	GGGACCTGCT	CAGGAGAGGG	TGGCTCCTCT	GGGCCTCGGT
5951	CCCAGAGGGA	AGGAGAGAAG	GGGAAGGGAA	GGGCTGCTGG	CGATGGGGGG
6001	ACTGTGTCGG	CTGGCCTTGG	CGGTTGCCCG	GGCCCTGGCA	GCTGGGGTGC
6051	CATGTGGGCT	GGGCGGGAGG	GGCCCTCTCC	CCCAGGGAGC	AGGCTGGCTT
6101	CGGTGGGAGC	AGATTGTGTT	TACACCTTCC	CCACACACCC	AGCCCACGCT
6151	CGCCTCTTAT	TCCCCGGGAC	TCTCCCACCC	CTGGGCTCTC	TCTGCACCAC
6201	GGGCACGTTT	GCAGCTCCTC	TCCTGCTGCA	GGAAGTTGCC	GCCCTCAGCA
6251	GAGMGCTCCT	CTACAGAAGG	CTGCCAGGGC	CCAGGCGCTC	CCTCCTCGGC
6301	CCACTATCTC	CCGTCTGTTG	GGGGGACCCA	GTGTCCCCAA	GAGGCTGAAT
6351	CCACCCACCC	CCCATTTCTT	TGGAAAACAG	CTGCTGCTTG	GGAATGGGGG
6401	CAGGAAGGAA	AGCCCGGGGG	GCTTGGCAGA	CTTGACCATA	ATAGGAGGGA
6451	AGGGATTAAG	GGCAACCAGA	GAGAGAGGGC	CGAGAGAGCC	GGGGCGCCTC
6501	TGGCCTCAGG	GTGCATGAGA	TAATGTAGAA	TTTAAGCTCG	GGGAGTCCAG
6551	CTCCAAGCTC	TGGATTTGAA	TCTTGACTCC	ACCATCACTT	TCCAGTTCTG
6601	TGGCCTCGGG	TGGGTTACTG	AATGTAAACC	TGTCTCAGAG	TTGTAAGGGT
6651	TAAATTAGAT	AATGGGTATA	AAGTGCTTCG	CGCACTTAGT	AAGCACGCAG
6701	TATATCTGAG	CCCAGGGTGG	GGGGACAGTG	TTTGTGAGCT	GTCAGCCACT
6751	GAACAACCTG	TCACTTTGCA	ACAACCGTAG	GTTCAGAACA	GCTAGTCCTT
6801	TACCTCCTCA	CCCCATGGCC	CTTCTGCCC	TGTCTTTCCA	CATACACAAC
6851	AGCAGGGTGA	TGGGCAGTTC	TGGAACAAAC	CAGAGCCCAG	CACAGGGGCA
6901	CCTGGTAGGA	CCCAGCACCC	GGGAAGGCTG	GACGATGGAG	CACCACGGTT
6951	GCYTCTGGGT	GCCTGGAACC	CTGTCCCCAC	CTCCAGTGGG	AGTCCTGACC

Figure 1C

7001	TGGACATCTT	CCCTCCAACT	GGCTCTGCGW	CCCCAAATGA	ATCTCAGCTC
7051	CTAGAGAAGA	CAGGAGGCCA	TGGCCCTGGT	GCCTTTATGG	TCCTCTGTCT
7101	GAATGCTAAT	CTCTTTACTG	GCTGGAGCCT	GAGTGACAGG	GAAAAGGCGG
7151	TTCTGAGCTG	CAGGGTGGCC	GAGGGCGGCA	GGMGGGAGCA	GGGAGGTGCT
7201	GTTGTCTGCT	ACTTCTGTGG	CTGCTGCCAG	TCTCTCCTRG	AGATGGGAAC
7251	ATGACCAGAG	AGCTAATGAG	GTGGCGGGGG	TGGGGGTGGG	GGAGAAAGGG
7301	AGGCAGACGG	AGCAGCTGCA	GCAGCTGCCA	CTGCCCTGTG	TCACCCCAGG
7351	GTGCAAATGC	CACCACGGGG	AGCACCCCGC	CCATCCCGAA	CTGTGTGGCT
7401	GTGCAGATGC	GGGCAGGATG	GTCTTGGGCA	CAGGCCTTGG	TCCAAGACCA
7451	GGCAGGCGTG	GTAATTGATC	TGAGGTGGGC	ATCATGGCAC	AGGAGCTGGT
7501	CCCAGGGGTG	CCCGGGGACC	TTTATAGAAC	CTCAGTCGGG	AAGAAGCCCA
7551	AGACCTTGAG	CCAGAGGGAA	GTAATGCTTC	TTTGTGAGCC	TCAAAAGGAG
7601	GGAAATGGCC	AAGGTTTACA	GTAATATAAT	GACACTAATA	TTATTATTAA
7651	TAATGGCTAA	TGTGTCTCAA	ACGCTTCTTA	CGTGCTAGGC	GCTGTGCCAA
7701	GTGCTTTATT	TATATGCATT	GTCTCATTTA	TGGGGCAGGA	ACTGTTGTCA
7751	GTCTCATTTA	CCCAATAAGG	AAAGTGCTTG	CTCAAGGTCA	CCCACAGTGA
7801	GTAGTGAAGC	CAGGACGTGT	TCCCCGGCAA	GGTGATGTAA	AAGCCTGTGA
7851	AGGTRTTGGG	CCTCGAGGAC	ATCCTGGGAG	TGTGACCTGT	CCACCAGGGC
7901	ACAGGGCATG	AGAGCTGGCA	ACCCTCCCTG	GTGATACTGC	CGCTGCTCAG
7951	TCTGCAGAAA	CTCATCATTC	CAGGCTGGAC	CAGACTCTGG	GCCCCGAGGG
8001	CAGTGACCAG	AGCCACCTTT	CCAGGATCTG	TCATGCTCCT	CAGGGAGGAA
8051	GCAGTGGCCA	CTGGCAGGGA	TGACAGATAT	CAAGGTTGTC	ACTCATTGCT
8101	GCTGTTGCTC	TGCTGTTTCC	TCCAACCAGG	GGCAGAGCCC	TGGGGGTAAG
8151	GGAGGGTGGC	AGCCAGCAGC	CCAGCCAGAG	AAGGAGGAGC	CAGAGGAGGA
8201	AGGCTTTGTT	GTTTGTTTTT	ACAGGGGGAY	GGTGCAGGGC	TTTAAGGAGG
8251	TGGCTTCAAG	ACCTGCTGAC	TTTAGCCATA	AACTGGTACC	TAAGGGTGCT
8301	GGACCCTCTC	TGTGGGATAC	ATATGCCCCC	TAGTGGGGAT	TAAGCCTGGA
8351	GGGTGGCTGA	GAA <u>AATTTAAA</u>	GCAAAACAAA	ACAAAAAAG	ATTTACTGAT
8401	AGGCTATATG	ACCTCCGAAC	CTGGATAGGA	AGGGCCAGGG	CTGGCCCCCT
8451	GTGTCCCCGA	GATTGCACAA	GCACGCACAG	GTTTAAGACA	ATTTGCAGAA
8501	CCCAGGTGAA	CGAAGCATTG	AAAGAAATTA	TTTAATTTAT	TCCTTGGTCA
8551	TTTATTTAAG	AAGCATGTAT	CGGGAGCCTG	TGATGTACAC	ACCCTGTGGT
8601	AGGTGTTGGA	GTCAGACAGC	AATCAAAGGG	ACGGCGCCCC	ATGTGCCAAT
8651	GAGGACGACA	GAAAGATCCT	GGCCGAGGAG	GCCAGTTGTG	CAAGCTCAGC
8701	CGCTGCCTGC	CACGACTTTT	ACTTCTCTGG	ACCTCAGTCT	CCCCATGTAA
8751	TAGGCAGTGT	TGAACCTAAG	TGGGCTGGTG	CAGAGGATGG	GAAGGACCAC
8801	TGACTACCCT	GGTAAAATGA	AGGGGATGGA	CTTCTTGACC	TCGGGGGGGG
8851	CCCTTCCAGA	TTCAAGACAG	GCTACAGTGG	ACAGTGTTTG	GAGGTGCTGA
8901	CAACGGTGAC	TCGCCCACTC	AGCAAGCGTG	TATGGAGCTC	CTGTATGCCA
8951	GGCATTGTGG	GTGGCAGAAA	TGAAGCRCC	AGAAAACCTG	ACAAAACCTGA
9001	AGAAGCAACA	GACACTTGAC	TACAAGGAAC	ATCCAAGATG	GTGATCCCGT
9051	GACCACCTCA	GCATCTACCT	CCCACAGGTC	CCTGCCTGAG	CACAGGGAGG
9101	GGAAACCCAG	AGGACTGCAG	TGGTCTTGTT	CAGCTGAGGA	GACAAGATCA
9151	GAGCTCAGAA	CAGTGTGCTG	TTCCTAAAGA	TATACACACA	CATCAATGGC
9201	ATCTCCAAAA	CAGACACAAC	GAAGATGATC	CAATGGAGAA	AGAAAAGCCC
9251	TTTTGAGGAA	ACACAAAAAG	TGCTAACCAT	AAAAGAAAAA	AACAGATAAA
9301	TTGGACTTGA	TCAAAATTCT	TGGAAAGACT	GGAAGAGAAT	ACTAGCCAAG

Figure 1D

9351	CAAAAATCCG	AACAAGGGCC	TGTATCCAA	ATATATAAA	AACTTTTACA
9401	ACTCAATAAG	AAGACGACAG	CCCAACGGAA	AAGTGGGGGA	GGGTTTTAAT
9451	AGACACTTCG	CAAGAAACTA	GACATATGGC	CAATAAACAC	ATAAAAAGAT
9501	ACACAACATC	CTAAGCCATC	AAGGAAATGC	AAATTAACAC	CACAATGAGA
9551	TACTACTGCA	CACTCACCAG	AATGGATAAA	AGATGGACCA	TAATAGACGT
9601	GGGTGAAGGT	GTGGAGCAAC	TTGTAACCCT	GTCATACGTT	GCTGGGAAAC
9651	CTGTTTGGCA	GTTTCTTAGG	ATGTAATCCA	AGAGGAGTGA	ACATGTAGGT
9701	CCACACAAAG	ATTTGTACAG	AGATGTTTAC	AGCAGTGTTA	TTATCAATAA
9751	TTAGTATCCA	AACTGGAAAC	AACGCAGATA	GCCATCAAGA	GGTAAATGGA
9801	TAAAAAATAA	AAAAAATAA	AGGAGGCGGT	GTATTCATAC	AATGGAATAC
9851	GATTCAGCAA	TAAAAGGCA	TTGAGCTACT	ATGTGAGCCA	TAACACAGGG
9901	CAATGAGAGA	AGCCAGATGC	TAAAGAGCAC	CTACAGTATG	AATCCATTTA
9951	TAGGAGATTC	TAGAACAGGC	AATAACTAAT	CGGGAGTGGC	AGAAAGCAGA
10001	TCAGTGGTTG	CCCGGGGCCA	GGGCTGGATA	TGGACACTGT	GAAATAGCAG
10051	GTTGGTACCC	TCCAGGGGGA	TGGAGATGTT	CTAAATTGAG	ACTGGGGTTG
10101	TGGTTTTATG	GGTGTATCAC	TGGCTGGACT	ATTTTAAATG	GATGCACTTT
10151	GTTATATGTA	AATTATACCT	CAATAAAGAT	GACTTAAAGA	GTTAAAAAAA
10201	AAAAAATAA	AAAGAACCAC	GAGAATGAAR	ACCTGATCCT	TGTCTTGCTT
10251	ACAGTCTAGT	GAAAACGMCA	GATGTGAAAA	CAAACAACCA	TAAGGCGGTG
10301	AGTAGCCTAA	GAAGCATGCT	CAAATAACAA	GAGTTCTGTT	TATGAAGGGC
10351	TCCCTCGCGC	CAGACCCACA	GAGGTGGCTT	GGCGTCACTG	TTCTAGAAGT
10401	CCAGATAAGA	AAAGAGGCTG	AGATGGAGGG	GAAGTTGTTC	ACGCAGGATT
10451	ACTCAGCTAG	AATCAGCAGG	CCTGGGACTG	GGCTCCAAGG	CTGCCTGGGT
10501	TCAGAGCAGG	TGCCACAGCA	GCCTGTGGCA	GGACACCGAG	CAGAGAGCTC
10551	GGGACTGTTG	CAGCTTCTCA	GGTGAGACTT	TGCGGAGGAG	GTATTGACAC
10601	AGGAGTTGGA	ATTTGCTCAG	CAGAGTAGAG	GATGCGGGGA	AGGAAATTTT
10651	AAAGCAAAGG	GAACAAACAA	TATGAGCAA	GGCTGGGCAA	CACTTGTGAG
10701	AAGGCAGGGT	TCCTGGGAAT	GGAGAGACGT	GTCCCGAAAA	GAGCAGAAGA
10751	GGTCAACAGG	ATATTACATG	TTCTTCGCAT	TCACTTATTT	TTTTAAGAAC
10801	CTATTAAGCA	ATAATTTTTA	CGAGAGGCAA	CAGCTCTGCA	GGGCAGGCAA
10851	GTGAWGTATG	TGCTCTTGGC	AAACGCAGGG	AAGAACCAC	CGTGATGCCA
10901	AGGTTGCCTC	TTTAGGGAAA	GGGGTTCTCC	CTGTGACATT	TCTCCTCCTC
10951	CAGGAGGTTA	AGGCTGTGTT	CCAGGATCCC	AGGTTTCTGC	TGAACACCCT
11001	TTGTGGCACT	CTTTCACGGT	CCTGAGAAAT	CCCAGGAGGA	AAAAAATAA
11051	AACAAAACC	CGCCTGTGCT	TTTATGCTGG	GCTTTCTGGC	TGGAGGAAGT
11101	CAAGTCACTG	GAGCGAAGCA	AAATGTGTCA	CACTGTCATG	GTGCGTTCTT
11151	CTGGAAACTC	AGCACAGCAG	TGAGGTTTGG	AGGCTTTGAG	GCTGGACTGG
11201	CTGAGGTCAG	ATCTCAGCGC	TCTTTCACAC	TGATTACTTT	CCCCTTTCTG
11251	CACTTTGGCT	TCTTTAGAAG	ATTGCAAAAG	AGGGGTGATC	ATAAGAGGGC
11301	AGATGTGAGA	ATGAAGGGAC	AGTACGTGCA	ATGTGCTCAG	TCAGACTCAT
11351	CGAGTCTGAG	ACGTTAATTT	AGCCTGTATA	GCCTTTTGTA	TGACAGTCAG
11401	TCCTCCATAA	ATCAGTTTTT	TAAAAAGAAG	GTGCTTAGAG	CAGAGCCTGG
11451	CCCAGAGCAA	ACATTTAATA	GACAGTAGCT	TTTGTGTTTT	CAAAAAGGTG
11501	ACATGCACAT	GTCATCCCTT	TTATTTTGCT	GTGACCCGTT	CTTTCAGAGA
11551	ATTATAATGA	AGCGGGATTT	GGGACATGTT	GATCATATCA	TTTAGGATGA
11601	TTGTGACTCT	TAACAGAACA	CCCAACTTAG	GGTGGCTCAA	ACAGGAAGGA

Figure 1E

11651	GATTTCTAAA	TCTCACATTC	TGGGGCGCCT	GGGTGGCACA	GTTGGTTAAA
11701	CATTCGACTC	TTGGTTTTGG	CTCAGGTCAT	GATCTCAGGG	TTGTGAGATG
11751	GGGCCCTGTG	TTGGAGTCTG	CGCTCAGCTC	ACAATTCTCT	CTCTCCTCCA
11801	CTTCTGCCCC	TCCTGCCCTC	TCTAA <u>AATAA</u> A	CATTTGAGG	GTTTTTTTAA
11851	AAAGATTTTA	TTTAGTTAGT	TGAGAGAGAG	ACAGACAGAG	ACAGAGAGAC
11901	AGAGAGTGAG	CATGTGTGAG	CACAGGTGGG	GAAGGGCAGA	GGGAGCAGCA
11951	GAATCCCTGC	TGAGCAGGAA	GCCCAACACA	GGGCTTGATC	CCAGGACCAA
12001	GATCAAGACC	CGAGCCAAAG	GCAGATGCTC	ATCCAACCTGA	GCCAGCCAGG
12051	CAACCCTAAA	<u>ATAAA</u> TGTCT	TTTTTTAAAA	AATCATCCTG	TGTTTCACTG
12101	AAACTAACAT	GCCATTGCTT	GTGAGATGCC	CCTTGCATTC	AGAAAT <u>ATTA</u>
12151	<u>AAATATAAA</u> A	ATGTGTGTCT	TTGARTTGAA	ACAAAAGGTC	TGAAGGTAGG
12201	GGGCTCTAGG	ACTGGTAATT	TGGCAGTTCA	CCATGAGGAC	TCTTTGTCCT
12251	TTGTTTCCAC	TCTGCCATCG	TCAGACCTTA	GGCTCTGGCT	TTGAGGCAAG
12301	CCTCATGGAT	GCAAGATGGC	TGCCAGGGCC	TCAAGCATCA	AGTCTTCAGA
12351	GCCTCCCAA	GCCAGAAGAG	AGGCTGCTGT	TTTTAAAAAC	AAGAAAAACT
12401	TTCCCAAAC	TTGCTTAATT	GCATCACAAA	CCCTTTTCTG	AATTCCTGGC
12451	AGAAGGAATA	GATTTATCAT	AAGGGTCTGG	TGCCGACTCT	TCAAGATTCG
12501	CCCTTAGGGC	CGGGGAGGAG	CTTGCCTCCA	CTGAAGCACC	GAGCTCCAGT
12551	TCTGTTGTGA	GATGGAGGAA	GAACAGCTGT	GAGCTGGCAA	TGAGCAGCGC
12601	TGCCATACAG	ATRAACCGCC	TGTGAATCAC	CGGTCAACTG	TGCCCGACAG
12651	AAGCAGCTGA	CTGCTTGGGA	TATTCCTACC	CACCTTCCTG	TTCCTATCAA
12701	CAATGGTAGA	GCTTCCTCTC	CAGGTTAAGA	AATTAACCTC	CATATTCCAA
12751	AGACTTGGTT	TCCTATTAAT	GTGGCTTTTCG	GGTACCGTAT	CCAAAATCCT
12801	ATCCGGATGG	AACCCAGTGA	GTTAGCCACC	TGAGCACAGC	AGGCCAATGG
12851	ACTAGATTTT	ACCTCCGTGC	TCAGAGCCAA	GGCCCCCTGA	CCGCACCGAG
12901	GACTGTGGCC	TTGCTCAGCC	TGGGATCTAC	TTCTGTCACT	GACCACTAGA
12951	TTGGGGGACT	CCGTGTCAGT	GAATACAGAT	CCATGCTAGC	CTAGGATGAC
13001	GGCTACGTAA	CAATTCCACT	GCAC <u>ATAAAA</u> A	<u>ACTCAAGTGT</u>	CCCAGACCTC
13051	GGGGCGCCTG	GCTGGCTTAG	GGAGGACTGA	CTCTTAATCT	CAGAGTCTTG
13101	AGTTCAAGCC	CTGTGTTGGG	TGTGGAGCCT	ACTTAAAAAA	AAAA <u>GAAGA</u>
13151	<u>AGAAGAAGAA</u>	<u>GGAGAAGGAG</u>	<u>AAGGAGAAGG</u>	<u>AGAAGGAGAA</u>	<u>GGAGAAGGAG</u>
13201	<u>AAGGAGAAGA</u>	<u>AGAAGAAGAA</u>	<u>GAAGAAGAAG</u>	<u>AAGAAGAAGA</u>	<u>AGAAGAAGAA</u>
13251	<u>GAAAGAAGAA</u>	<u>GAAGAAGAAG</u>	<u>AAGAAGAA</u> TT	AGAAATCACA	ACATTGATGC
13301	TTTGATCTCC	ACAGCTCTGA	ACTCCCGCCT	GCTCCTTCAG	AAATCTGATG
13351	CGTTCTCTGT	TGTCTTTCCA	CTGATTTTTT	TCTTTTTTTT	TTAAGATTTT
13401	ATTTATTTGA	CACACAGAGA	GATCAGCAGG	GGGAGCATCA	GAGGGAGAGG
13451	GAGCAGCAGG	CTCCCCGCTG	AGCAGGAAGT	CCAACATGGG	GCTCAATCCC
13501	AGGACCCTGG	GATCATGACC	TCAGCCAAAG	GCAGATGTTT	AACCCACTGA
13551	GCCACCCAGG	TGGCCCTGAT	TTTTTTTTTA	AGATTATTTA	TTTATTTTAG
13601	GGATCCCTGG	GTGGCGCAGC	GGTTTACCGC	CTGCCTTTGG	CCCAGGGCGC
13651	AATCCTGGAG	ACCTGGGATC	GAGTGCCACA	TCGGGCTCCC	GGTGCATGGG
13701	GCCTGCTTCT	CCCTCTGCCT	ATGTTTCTGC	CTCTCTCTCT	CTCTCTGTGT
13751	GACTACAATA	AATTAATAAA	TATTTTTTAA	TATTATTTAT	TTATTTTTAA
13801	ATATTTTATT	TATTTATTCA	TGAGAGACAC	AGAGAGAGAG	GCAGAGATAC
13851	AGGCAGAGGG	AGAAGTAGGC	TCCCACAGGA	CTTGATCCCA	GGACCCAGG
13901	ATCACGACCT	GAATCCAAGG	CAGATGCTCA	ACCACTGAGC	CACCCAGGTG

Figure 1F

13951	TCCATTAAA	GATTATTTAT	TTGACAGAGA	GAGAGAGAGC	AGGAGCAGAG
14001	GGGCACAGGG	AGAAGAAGAC	TTCCTGCTGA	TCGAGGAGCC	CGACATGGGG
14051	CTTGAACCTA	GAACCCTAAG	ATCATGACCC	AAGTTGAAGG	CAGATGCTTA
14101	ACCAATGGAG	CCACCAGGTG	CCCCATCCTC	CCCTATTTCT	GGACTGCCCA
14151	GGCAGTGTGC	CCTCTGCCTG	CCACTCTTCC	TGCTTGTGTG	CTCTATTTTT
14201	<u>C</u> <u>AAATAAATA</u>	<u>AATTAATTAA</u>	<u>AAAATAATAA</u>	TCTTGAGGCA	CCTGGGTGGC
14251	TCAGTGGTTG	AACATCTGTC	TTTGGCTCAG	GGCGTGATCC	TGGGGTCCTG
14301	GGATCGAGTC	CCACATTGGG	CTCCCTGGAT	GGAGACTGCT	TCTCTCTCTG
14351	CCTGTGTCTC	TGCCTCTCTC	TCTCTGTGTG	TGTGTGTCTC	TCATG <u>AATAA</u>
14401	<u>ATAAATAAAA</u>	GGGATCCCTG	GGTGGCACAG	TGGTTTAGCG	CCTGCCTTTG
14451	GCCCAGGGCG	CGATCCTGGA	GACCTGGGAT	CGAATCCAC	GTCGGGCTCC
14501	CGGTGCATGG	AGCCTGCTTC	TCCCTCTGCC	TATGTCTGGG	ATCCCTGGGT
14551	GGCACAGCGG	TTTGGTGCCT	GCCTTTGGGC	CAGGGCGTGA	TCCTGGAGAC
14601	CCGGGATCGA	ATCCACATC	GGGCTCCCGG	TGCATGGAGC	CTGCTTCTCC
14651	TTCTGCCTGT	GTCTCTGCCT	CTCTCTCTCT	CTGTGTGACT	ATCATG <u>AATA</u>
14701	<u>AATAAATAAA</u>	<u>ATCTTAAAAA</u>	<u>AAAAATAAAT</u>	<u>AAATAAAA</u> TC	TTTTTATTAG
14751	ATTTTATTTA	AATCTTTTTA	TTAGATTTTA	ATCTCACTGC	GTTTTGCTCC
14801	GGCCTCTCGG	CGCCTGCCCA	GCCACCCGAG	ACATGCCACC	TGCGGTGAAC
14851	CTGCTGCTCT	TCTACTAGGT	GTCCTGTCAG	GTGTGAAAGC	TCCACTGTAG
14901	ACCGTGGCAT	TGTGGCTCCT	CTCAAGCCCA	GAAGAATGCT	CCATGCTCCT
14951	CACACGCACT	AGCTGGCAAC	CGGTCTGGGA	CTCAAGACAG	CCCTGCTAGA
15001	GCCCAGAGCC	CCCAGTCTT	GCAGCCATCA	GCYCCTGCAG	CCTCTCCTCC
15051	TCACTCTGCT	TGCCATAAAG	TGGCTCAAAA	CCACGGAACA	GGTGCCCATC
15101	ATTCCCCTGA	GTAATTTTCAT	CCCAACCACC	CCTGCAAACA	CACAAAACCC
15151	TTCTTTGCTC	CTCTCCCCCA	TGCCCAAAG	CCCTATAGTA	AGACTGATGT
15201	ATAGATATAC	GAAGTTCAGT	ACATCTTAGT	GGTGAGAGTA	TGGACTCTGC
15251	AGGCTGGCCT	CAAACCTTGA	CCCAGCAAT	CACTAGTTGT	GTGAATTTGG
15301	GAAAGTCACC	TCATCTCTCA	CTCACCTCAC	CTCATCTGCG	AAATGCRGGT
15351	AGTGATAGWG	CCCTTCAGAG	GGCAGCGGTG	CACATTAAC	AAATTGGTGT
15401	GCGTTCAGTA	CTCCAGGAGT	GGACGGCGCA	TGGTAAGTGC	TACCYGGTAT
15451	CCACTCTCGC	TGTTATTTCGG	CCTGCAGCGG	GTCCCTTGCC	TCCATCCAAG
15501	CAGCTCTGGG	GAACTTCCAC	ATTCAAAACT	CCCTCTCCGA	GTCTGAAAAT
15551	GAAAGGAACT	TAGTTTTTCAG	GGAGAGAGCC	CATTCCCTCCT	TCCCTATTC
15601	TACAAAACCTG	TATTCAAGGG	CAAGACAGAA	ATGCAAGGGC	CAGTTTCATA
15651	AGACAGATGT	TACTGCCAAG	TGAGTCAATG	ATTATCTGTT	GTGTACGTGG
15701	GCAGAGGCAG	AGGAATAACA	ACCAGACTCT	GGGAGGCAAT	TAAAAAGAAA
15751	AAAAAAAAAA	GTAAGAGAGT	GTCTCATGGA	GCGCCTGGGT	GGCTCAGTCC
15801	GTTAAGCCTT	GGACTTTTGG	TTTCCCCTCA	GGTCATGATC	TCAGGGTCGT
15851	GGGACCCAGC	CCTGGGGCGG	GCTCTGTGAT	CAGTGGGGAG	CCTGCTTGAG
15901	ATTCCCTCCT	TCTGCTGTGC	ACACTCTCTC	TCT <u>AAAATAA</u>	<u>ATA</u> CGTCTTT
15951	AGAAGAGCAA	GCGAGCGAGA	GATGCTTCCC	GCCTAGAAGA	GCTTACAATC
16001	AAATCAAGGG	AGGCAAACAT	AAACAAGTGT	GGCAACTTGA	TAATAAGCAC
16051	CTGCGACCTA	TGGCCATACA	CAGAATAACA	TAACCCAGAC	TAAATGCCAC
16101	TGCATAGTCA	CTAGCGGGTT	GATGACAACG	GGGGGAGGCT	AATGCTGAAA
16151	AGGCCTTTCT	GTCTTATAAG	TTTAAACTAA	TTTCTGGGGG	CACCTGGGTG
16201	GCTCTGGTTG	AGCATCTGCC	TTTGGGTTCGT	CGTCCAGGG	TCCTGAGATC

Figure 1G

16251 GAGTCCCTCA TCCGGCTCCC AGCCCCGTAG GAGCCTGCTT CTCCTCTGC
 16301 CTCTTCCTCT CTGTCTCTCA TGAATAAATA AATAAAAAATT TTAAGGGATG
 16351 CCCGGGTGGC TCAGCGGTTT AGCGCCTGCC TTTGGCCCAG GGTGTGATCC
 16401 TGGGGTCCCG AGATCGAGTC CCACATCGAG TCCCACATCG AGTCCGGGA
 16451 TCGAGTCCCT GCAGGGAACC TGCTTCTCCC TCTCCCTGTG TGTGTGTCTC
 16501 TCTCTCTTTC TGTATCTCTC ATGAATAAAT AAAGAAAATC TTTAAAAATA
 16551 AATAAATAAA AACAGTATTT AAAAAAATGA ACTAATTTCC AAGTAGGTGT
 16601 AAATTCTGGC TCGGACTAGT GAATGGCTCT GGCTCTGCTG CATCACCCAC
 16651 CGCCAGGGCT CTGGGCCGCT CCGAGCCCCG CTCGCCGGCG CCCCTGCCC
 16701 CCCGGGCCTC CCGCCTTAC CCACACCCGC AGGGCGGCGG AGCCCTAGGC
 16751 CCAATCGGCC CCGGGAACCT GCCGCCTCTT CTCTAGCGCA ACCCAGCACC
 16801 CAGATGACCC CTTTTCCGCC CCAGGTGCAG TCCGGCCGGG CCCTGGTGTC
 16851 CTCACCCGTT CCCCTAGGGA GACCCCTCTC GAACCTTCTG CGCCACCCTA
 16901 CTCTACGCCA GGGAAAATCT GTGCACTCAG TAGATAAAATG CTTGTAACTG
 16951 AAGCAACCGT CTCCGTGGCT CCAGAATCGC GCTGAGGATG CTGCTGCCGC
 17001 ACCCCACCT CCCC CGGCTC CGGCGGAGGT TGTTTGGACT ACACTTCCCA
 17051 TGAGGCCCT CTCAACATCG CGATAACTCT CGCGAGACCG CTGGGAAGAG
 17101 TTGTGCGCAG GCGCAGCCCC GCCTTCTTGT CGAGGCAGGC CGCGTGCCCG
 17151 GCAGTCATGG CGGCTCCTTG CTGGCCCGAC CGGGACAGGG AGTCTGGAGY
 17201 CTCTGGCTGT GGTAAGGTTG TCGAGGCGGG CAGACGGGAT CGTCCTTGGC
 17251 CCGGCGCTAG TTCGCTCGGC CTCCCTTTCC TCGGGGGCGG GATGATGACG
 17301 GTAAAGCCGG TCTTCCTCGT AGGGTGGTTG GGTTAGTTGA GATGCTGGAT
 17351 CGGAAAACGC TTTCTGAGCG GCGCGAGTGT TGACGATCGA AGGGAGAGAG
 17401 CTCAGGCCCC CCTTGAGGTC AGAGGGCCCC TCCTGGGGGG GGGGGTCCCTC
 17451 CAGCCTGTGC AGCCCCGTGT GTGCCCTGCG GGTCTCCCGG GCCCGCCCAC
 17501 GGGAGGCTGC CGGTGGTAGT TCTTAATCCA CATCAAGTGT TAACGTGAGG
 17551 GTCCTGGAGT GCCCCGAGGT CGGCCCTGGT CAGTGGTTCG TATTCAGTCC
 17601 TACAGATAGT AGTAAAGGGG CTTGTAGATT TTGGAAAGCC ATAATGCTCT
 17651 GCGCCCTACC TTCCATGTTT ATTTTTTTTT CCCTCTCTCT TCCCGTACAG
 17701 GGTTTTCTTT GCGTCGCAGA CCTGCAGGTT GAAGCTTAAA AGTAGCGAAT
 17751 GGGGAGCCCT GTGAAATGGG TAAGGATGGG TGCTGGCAGG GCCCGGGTGG
 17801 TGACCAGAAG TGAGAAAGTC GAGATGGTGG GCAGGCCTGC CACACCCGGC
 17851 CGCCGCACGC TTTACTTTAC TAATTTTATT TTTTTTTAAA GRTTTAATTA
 17901 ATTAATTAAT TAATGATAGG CAGAGACACA GGCAGAGGGA GAAGCAGGCT
 17951 CCGTGCCGGG AGCCCGACGC GGGACTCCAG GATCGCGCCC TGGGCCAAAG
 18001 GCAGGCGCCA AACCGCTGAG CCACCCAGGG ATCCCCTTT ACCGATTTTA
 18051 AGTTCGGTTC TTAGGAACAC GTGGACGCAC GCATCCGGTT AGGGTGAGAA
 18101 GAAAACGGAC CCGGGTCTTG GAAGCGAGCA GGGCCTTGCC AGTGTGACTC
 18151 GCGCCGCTA GGTGTCACTG TTTGGATTCA AACCGGTTGC CGCGCACGAG
 18201 GTTGGCGGGG AGGCTTAGGA AATGGGCTTC GGTGGGGTTT GGAAGTATTT
 18251 GTGGATGATT TAAAGTTATC TTTGTCTTAA AGGGCTCTTT TGTGAAGAGT
 18301 TTTGATGCGT TGAGGCTCAG CTTTTTTTTT TTTTTTTTTT TAAGGTTTGT
 18351 ATTCATTTTT TCACAGAGAG GCAGAGGGAG GAGAAGCTTG CTGCCTGCAG
 18401 AGAGCAGGAT GCGAGACTCG ATCCCTGGAT TTCGGGATCA CGCCAGAGC
 18451 CAAAGGCAGA CACGCAACTA CTGAGCCACC CAGGCGTCCC GAGGCCCCAG
 18501 CTTCTTAAAT AACCAATCTT GAGAATAACA TCTTGACCTC ATTTCTCTTA
 18551 GAATATACTT TGTTACATTT CCCTTAGAGA TTAAAGGTGT TG

Figure 1H

1 AGTGGCAGCA GGAACCTCAG GATGGGCAGC AGTGGCTTGT GAGAGCCGGC
51 AGGGCCATTT TGGCCTTTCT CCTGCAGACT CTGTCCGGGA GGGGATGGGG
101 CAGCTGAGCC **ATGTR**CACCA CCCTCTTCCT ACTCAGCACC TTGGCCATGC
151 TCTGGCGCCG CCGGTTCCGCC AACCGGGTCC AACCGGAGCC CAGCGGAGCA
201 GACGGGGCAG TCGTGGGCAG CAGGTCGGAG AGAGACCTCC AGTCCTCGGG
251 CAGAAAGGAA GAGCCTCTGA AGTAAGTCTT CACCCGGTCA GGCGGAGCTC
301 GGCCCCAGGG AYTGGGATCA GCTGGCAGAG GCAGTTCAAG TCCCGGCTGG
351 CCTCTTACCC ACAAAGCATG CTGTGGTGGG AGCAGCAGCA GCAGCAAGAA
401 GAAAAATGGG AAAAAGCAGT CATCAAGAAG GTAGACTCCT CCCTTTGAGT
451 CCCTGGACCT GCCTGGCCTC CCTTTGCCCC AGACCCTGGT GGTGGGGCTC
501 CTGAAGCAAG GCCTGGCTGG GGCAGGCTGG AGGGCAAAGA CGCTCATTGC
551 CCTGGCTTGG GCTCCCTTCC TCTGAGATCC TGAGGATAGT CTGAGGCAGG
601 CCCAGAGAGG GACTCAGGTT TCTTATGGAA GGRCTTCTCA TTCATCCCTA
651 ATATAATCCT TGCAATGACC CAAAAAAAAA AAAAAAAAAA AAAAA

Figure 2




Figure 3A

Figure 3B




Figure 4.

1

**IDENTIFICATION OF THE GENE AND
MUTATION RESPONSIBLE FOR
PROGRESSIVE ROD-CONE DEGENERATION
IN DOG AND A METHOD FOR TESTING
SAME**

This application is a Divisional of U.S. application Ser. No. 11/157,743, filed on Jun. 21, 2005, now U.S. Pat. No. 7,312,037 which in turn claims priority to U.S. provisional application No. 60/581,499, filed on Jun. 21, 2004, the disclosures of which are incorporated herein by reference.

This work was supported by Grant No. EY006855 from the National Institutes of Health (NIH). The Government has certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates generally to a class of genetic diseases, observed in canines, termed progressive rod-cone degeneration ("prcd"). More particularly, the invention relates to a gene and a single nucleotide mutation in the gene associated with progressive rod-cone degeneration in dogs.

BACKGROUND OF THE INVENTION

Progressive Retinal Atrophy (PRA) is a heterogeneous class of retinal disorders that share a broadly similar clinical disease phenotype, and affect the dog (*Canis familiaris*) (Aguirre, 1976). The clinical features include: initial night blindness followed by reduction in photopic vision leading to complete blindness; reduction in retinal vessels, and retinal thinning; abnormalities in an electroretinogram ("ERG"); and the development of cataracts. Diseases of this group are typically inherited by means of an autosomal recessive gene defect although dominant and X-linked forms of PRA also are recognized (Kijas et al., 2002; Zhang et al., 2002). PRA may be classified into developmental and degenerative diseases. The developmental class comprises several genetically distinct diseases expressed cytologically in the immediate post-natal period when visual cells in the canine retina begin to differentiate (Acland et al. 1989). In contrast, the degenerative class represents defects in which photoreceptor cells degenerate after having differentiated normally—this class includes the specific disease termed progressive rod-cone degeneration (prcd). This specific form of PRA is an autosomal recessively inherited, late-onset retinal degenerations affecting several different breeds of dog (Aguirre and Acland, 1988).

Mutations at the prcd 'gene locus account for all of the autosomal recessive late-onset hereditary retinal degenerations recognized to date in dogs. By cross-breeding experiments, it has been determined that the prcd gene locus is responsible for progressive retinal atrophy in poodles (toy, and miniature), cocker spaniels (American, and English), Labrador retrievers, and Portuguese water dogs (see, e.g., Aguirre and Acland, 1988, Aguirre and Acland, 1991; Pearce-Kelling et al., 2002). Cross-breeding experiments suggest the same mutation in the F04 gene (which is gene responsible for prcd) is also present in several other breeds either in dogs affected with prcd; or carriers of the disorder. However, based on clinical and genetic parameters consistent with disease caused by mutations at the prcd gene locus, other breeds of dogs suspected of having prcd as the form of observed progressive retinal atrophy include akita, basenji, border collie, English mastiff, English springer spaniel, Havanese, lowchen, samoyed, standard wirehaired dachshund, Tibetan terriers, Bernese mountain dog, and miniature schnauzer. Depending on the breed of the dog, different mutations responsible for allelic variants of the prcd gene locus can regulate the rate of progression, but not the phenotype, of photoreceptor degeneration.

2

Clinical diagnosis of prcd disease is complicated by the need for sophisticated testing methods such as ERG, and by the late onset of the disease. The age at which the disease can be diagnosed by current methods may be past the dog's reproductive life. For example, in English cocker spaniels, progressive retinal atrophy may be diagnosed by ERG at three years of age, and by ophthalmoscopy at 5-8 years of age. This late age of diagnosis results in the dissemination of the undesirable trait within the population, and an increase in the disease frequency.

The estimated prevalence of progressive rod-cone degeneration differs among affected breeds. It is believed that approximately 2% of Labrador retrievers more than 2 to 3 years old are affected with progressive rod-cone degeneration; if so, then the proportion of Labrador retrievers expected to be heterozygous at the prcd locus could be as high as 24%. In poodles and cocker spaniels, the disease rate is higher than that observed in Labrador retrievers, and hence, the carrier rate would be expected to be higher. From the results of a survey of Portuguese water dogs, the calculated carrier frequency is approximately 40%.

Traditional measures for controlling inherited diseases in a population included performing "test" matings to identify carrier dogs, and to eliminate the identified carriers from breeding programs, thereby reducing the frequency of genetic disease in a breed. In a test mating, the dog being evaluated as a potential carrier of the genetic disease is mated with a dog known to be affected with the disease. Progeny are then observed for absence or presence of the disease, and a litter equal to or larger than 6, all of which are unaffected offspring, typically "clears" the dog from being a carrier. While test matings have been effectively used for breeds having large litter sizes, and for diseases which are early onset, such a procedure is not practical for reducing the frequency of prcd. In addition to the disadvantages of test matings such as great expenses in time and effort incurred to clear a dog and that affected dogs can be born if the dog to be evaluated is a carrier, test matings are not particularly suited for detection of carriers of prcd because of the late onset of clinical symptoms associated with the disease, and because some of the breeds affected have small litters (too small for establishing statistical probability).

Although the gene carrying the mutation or mutations that cause prcd has previously been unknown, genetic linkage studies in prcd families have shown that the gene that causes the disease in dogs resides on the centromeric end of canine chromosome 9, an area that is homologous to the telomeric end of the long arm of human chromosome 17 (Acland et al., 1999; Sidjanin et al., 2003).

In spite of the extensive efforts in the art to find the gene responsible for prcd, until now the gene has remained elusive. Identification, isolation, cloning, and sequencing of the prcd gene would enable the design and manufacture of products useful for the diagnosis and screening for prcd. Therefore, there has been an ongoing need in the canine breeding industry for a genetic test that permits direct identification of dogs that have the prcd form of progressive retinal atrophy (e.g., before detectable onset of clinical symptoms), as well as permitting the genotyping of dogs at risk for prcd to establish if they are affected, carriers or genetically normal.

SUMMARY OF THE INVENTION

The present invention provides an isolated nucleic acid molecule encoding a novel disease-associated canine gene, referred to herein as the F04 gene. The invention further provides the F04 gene having a G to A mutation at position 1298 of SEQ ID NO:1. This transversion is associated with and is indicative of prcd.

The present invention also relates to a method for identifying dogs, which are genetically normal, carriers of, or affected with prcd disease. Genetically normal dogs are those in which both alleles of the F04 gene have G as the nucleotide at a position corresponding to nucleotide position 1298 of SEQ ID NO:1. Affected dogs or predisposed dogs are those in which both alleles of the F04 gene have A as the nucleotide at a position corresponding to nucleotide position 1298 of SEQ ID NO:1. Carrier dogs are those in which one allele of the F04 gene has G and the other allele has A as the nucleotide at a position corresponding to nucleotide position 1298 of SEQ ID NO:1. A change of G to A in the F04 gene at a position corresponding to nucleotide position 1298 of SEQ ID NO:1 is termed herein as the "prcd mutation". The nucleotide position 1298 in SEQ ID NO:1 also corresponds to nucleotide position 115 in the cDNA sequence shown in SEQ ID NO:3

The method comprises the steps of obtaining a biological sample from a dog and testing the biological sample to identify whether or not G is present at a position corresponding to nucleotide position 1298 of the F04 gene. In one embodiment, the method comprises detecting a G to A mutation at a position corresponding to nucleotide position 1298 of SEQ ID NO:1 in one or both alleles which is indicative of a dog that is a carrier of or a dog that is affected with (or predisposed to) prcd respectively.

The present invention also provides a method for selecting dogs for breeding. This method comprises obtaining a biological sample from a dog, testing the biological sample for the F04 gene having a prcd mutation in one or both alleles, and eliminating dogs with the prcd mutation from a breeding stock, or breeding the dogs with the prcd mutation with genetically normal dogs.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows the genomic sequence of the canine F04 gene.

FIG. 2 shows the sequence of the cDNA from the canine F04 gene.

FIG. 3 is a representation of restriction endonuclease digestion of amplified products from genetically normal, carrier dogs or dogs affected with prcd. FIG. 3A shows digestion with the restriction endonuclease *RsaI* and FIG. 3B shows digestion with restriction endonuclease *ApaI*.

FIG. 4 is an illustration of the experimental setup used to identify whether a dog is a carrier, is affected with or is normal with respect to the prcd mutation, using Pyrosequencing™.

DESCRIPTION OF THE INVENTION

This invention provides a nucleic acid molecule encoding a novel F04 gene located on chromosome 9 in dogs. The sequence of the wild type F04 gene is presented in FIG. 1 and details pertaining to the sequence are as follows.

Explanation of the Genomic Sequence

The genomic sequence of the F04 gene is 18592 bp long. The sequence listed in SEQ ID NO:1 includes, all polymorphisms identified heretofore. Nucleotide exchanges are shown in italics as follows: W=A/T; M=A/C; R=A/G; Y=C/T; S=C/G; K=G/T. Insertion/deletions are shown in italics and underlined. Sequence for the affected and alternative allele for all polymorphisms shown in the sequence are presented in a separate Polymorphism table (Example 2). Microsatellite at position 13,146-13,278 bp is also shown in italics and is boxed.

In the public domain canine genome sequence assembly (canFam1) dated July 2004 (<http://genome.ucsc.edu/cgi-bin/hgTracks?org=Dog&db=canFam1&hgsid=42443361>), the F04 genomic sequence (SEQ ID NO:1) is localized incorrectly to chr18:26,568,308-26,586,788. We believe this is incorrect, as we have established through our BAC contig, and by FISH and meiotic linkage mapping that, as predicted by comparison to the homologous regions of the human and mouse genomes, this canine genomic region is properly located on CFA9. This discrepancy does not affect the accuracy or the utility of the tests described herein.

Throughout this sequence, proposed exons and UTR regions are shown in upper case letters and defined exons are bolded. Intronic regions are in lower case letters.

Exon 1: bp 1-1,367

Includes a TATA box at position 727-731, three CRX binding sites at positions 1,122-1,128; 1,159-1,165; 1,177-1,183 and the ATG signal indicating the start of the ORF at position 1,294-1,296 all underlined and boxed.

The prcd mutation at position 1,298 is shown in italics, bold and boxed. The mutation is a change of G to A and is shown as "R".

Exon 2: bp 1,650-1,718

Exon 3: bp 3,746-3,826

Includes the stop codon at position 3,765-3,767 shown underlined and boxed.

Exon 4: bp 4,161-4,256

3'UTR: bp 4,257-18,592

Within this region there are several potential adenylation signals which are pointed out underlined and boxed. The region entitled 3'UTR has also been shown to contain regions of alternative splicing (indicated in bold), which further defines within this region:

Exon 5a: bp 4,806-5,399

Exon 5b: bp 4,839-5,399

Exon 5c: bp 5,093-5,399

Exon 6: bp 6,558-6,665

Exon 7: bp 6,927-7,164

Exon 8: bp 7,547-7,720

Exon 9: bp 12,275-18,592

The deduced amino acid sequence of a putative protein encoded by the F04 gene, based on the sequence of SEQ ID NO:1, and assuming a start site at position 1294 is shown below as SEQ ID NO:2.

Met Cys Thr Thr Leu Phe Leu Leu Ser Thr Leu Ala Met Leu Trp Arg Arg Arg Phe Ala Asn Arg Val Gln Pro Glu Pro Ser Gly Ala Asp Gly Ala Val Val Gly Ser Arg Ser Glu Arg Asp Leu Gln Ser Ser Gly Arg Lys Glu Glu Pro Leu Lys—(SEQ ID NO:2)

In this case, the prcd mutation would result in cysteine (the 2nd amino acid) being replaced by tyrosine.

The F04 cDNA Sequence (see SEQ ID NO:3)

Several splice variants of the F04 gene have been identified, all of which include the same ORF. The shortest full length splice variant is 695 bp long; the cDNA (SEQ ID NO:3) for this variant of the F04 gene is shown in FIG. 2. Those skilled in the art will recognize that potential future identification of additional exons, that do not alter the F04 ORF as described herein (such as a noncoding exon 5' to exon

1, or 3' to exon 3), will not affect the demonstrated association of the *prcd* mutation with PRA or detection of the *prcd* mutation as described herein.

Explanation of the cDNA Sequence:

The cDNA sequence embeds the ORF of 165 bp, located at position 111-275 (both start and stop codon are highlighted in bold). The mutation is located within the ORF at position 115 shown in italics, bold and boxed (Normal allele=G; mutant allele=A). Other polymorphisms (for examples: Y=C/T, nt 312 SEQ ID NO:3, Polymorphism# 55, Table 1; and R=G/A, nt 633 SEQ ID NO:3, Polymorphism# 57, Table 1) in the 3'UTR are not disease associated because both alleles have been identified on normal chromosomes. All cDNAs that include the F04 ORF incorporate exon 1 (bp 1-184), exon 2 (bp 185-253), exon 3 (bp 254-334) and exon 4 (bp 335-695), however, partial cDNAs obtained using different primer sets establish that different splicing variants in the 3'UTR can include at least exons 5 and 8 as defined in the genomic sequence. Other features are the same as in the genomic DNA.

Detection of the *prcd* mutation in the F04 gene can be carried out in any suitable biological sample obtained from a dog. In a preferred embodiment, the biological sample is any tissue containing genomic DNA. Suitable sources of biological sample include blood, hair, mucosal scrapings, semen, tissue biopsy, or saliva. In one embodiment, the biological sample is blood.

Dogs carrying the *prcd* mutation in F04 gene may be detected by testing either the DNA or the RNA, using a variety of techniques that are well known in the art. The genomic DNA used for the diagnosis may be obtained from a biological sample as described above. The DNA may be used directly or may be amplified enzymatically in vitro through use of PCR (Saiki et al., *Science*, 239:487-491 (1988)) or other in vitro amplification methods such as the ligase chain reaction (LCR) (Wu and Wallace, *Genomics*, 4:560-569 (1989)), strand displacement amplification (SDA) (Walker et al., *PNAS USA*, 89:392-396 (1992)), self-sustained sequence replication (3SR) (Fahy et al., *PCR Methods Appl.*, 1:25-33 (1992)), prior to mutation analysis. The methodology for preparing nucleic acids in a form that is suitable for mutation detection is well known in the art.

Detection of DNA sequence mutations, such as the *prcd* mutation in the F04 gene, can be accomplished by a variety of methods including, but not limited to, restriction-fragment-length-polymorphism detection based on allele-specific restriction-endonuclease cleavage (Kan and Dozy *Lancet*, 2(8096):910-912 (1978)), hybridization with allele-specific oligonucleotide probes (Wallace et al., *Nucl Acids Res.*, 6:3543-3557 (1978)) including immobilized oligonucleotides (Saiki et al., *PNAS USA*, 86:6230-6234 (1989)) or oligonucleotide arrays (Maskos and Southern, *Nucl Acids Res.*, 21:2269-2270 (1993)), allele-specific PCR (Newton et al., *Nucl Acids Res.*, 17:2503-2516 (1989)), mismatch-repair detection (MRD) (Faham and Cox, *Genome Res.*, 5:474-482 (1995)), denaturing-gradient gel electrophoresis (DGGE) (Fisher and Lerman et al., *PNAS USA*, 80:1579-1583 (1983)), single-strand-conformation-polymorphism detection (Orita et al., *Genomics*, 5:874-879 (1983)), RNAase cleavage at mismatched base-pairs (Myers et al., *Science*, 230:1242 (1985)), chemical (Cotton et al., *PNAS USA*, 85:4397-4401 (1988)) or enzymatic (Youil et al., *PNAS USA*, 92:87-91 (1995)) cleavage of heteroduplex DNA, methods based on allele specific primer extension (Syvanen et al., *Genomics* 8:684-692 (1990)), genetic bit analysis (GBA) (Nikiforov et al., *Nucl Acids Res.*, 22:4167-4175 (1994)), the

oligonucleotide-ligation assay (OLA) (Landegren et al., *Science*, 241:1077 (1988)), the allele-specific ligation chain reaction (LCR) (Barrany, *PNAS USA*, 88:189-193 (1991)), gap-LCR (Abravaya et al., *Nucl Acids Res.*, 23:675-682 (1995)), and radioactive and/or fluorescent DNA sequencing using standard procedures well known in the art.

Further, several new techniques have been described including dynamic allele-specific hybridization (DASH), microplate array diagonal gel electrophoresis (MADGE), Pyrosequencing™, the TaqMan system as well as various DNA "chip" technologies such as the Affymetrix polymorphism chips. These methods require amplification of the target genetic region, typically by PCR. Still other newly developed methods, which may not need PCR are based on the generation of small signal molecules by invasive cleavage followed by mass spectrometry or immobilized padlock probes and rolling-circle amplification. Several of the methods known in the art for detecting specific single nucleotide polymorphisms are described in U.S. Pat. No. 6,720,141 and the description of these methods is incorporated herein by reference.

As will be appreciated, the mutation analysis may also be performed on samples of RNA by reverse transcription into cDNA therefrom.

Any one or any combination of such techniques can be used in accordance with the invention for the design of a diagnostic device and method for the screening of samples of DNA or RNA for *prcd* gene mutation of G to A at a position corresponding to nucleotide position 1298 of SEQ ID NO:1 of the F04 gene. Thus, in accordance with the invention, there is provided a nucleic acid based test for *prcd* gene mutation which comprises providing a sample of a dog's DNA or RNA and assessing the DNA or RNA for the presence of the *prcd* mutation. Samples of dog DNA or RNA (or genomic, transcribed, reverse transcribed, and/or complementary sequences to the *prcd* gene) can be readily obtained. Through the identification and characterization of the F04 gene as taught and disclosed in the present invention, one of ordinary skill in the art can readily identify the genomic, transcribed, reverse transcribed, and/or complementary sequences to the *prcd* gene sequence in a sample and readily detect differences therein.

Accordingly, in one embodiment, the present invention provides nucleic acid fragments for detection of nucleic acids wherein the mutation is present. In general, the detection methods are based on DNA hybridization techniques, wherein hybridization to DNA sequences is performed under stringent conditions such that a change in one nucleotide can be detected. Optimal stringency is normally obtained by adjusting the reaction temperature and/or salt concentration so that the probe will only hybridize to its specific target, although those skilled in the art will recognize that alternative methods of optimizing for target specific hybridization are readily available.

Thus, allele-specific probes can be hybridized under conditions that are sufficiently stringent so that there is a significant difference in the intensity of the two alleles. Preferably, the hybridization conditions are sufficiently stringent so as to produce an essentially binary response (i.e., the probe hybridizes to one but not the other allele).

Further, primers can be designed which hybridize to a target sequence such that upon amplification, products are generated which contain the *prcd* mutation site. The primers should be long enough to be useful in reactions such as polymerase chain reaction (PCR) process or as probes in a ligase chain reaction (LCR) procedure. Generally fragments which are at least twelve bases in length are considered suit-

able for amplification reactions. The amplification products can be subjected to restriction endonuclease treatment and identified by denaturing gradient gel electrophoresis so as to distinguish between the amplification products from the two alleles.

Suitable fragments useful for hybridization can be identified from the sequence of the F04 gene presented herein or may be identified by hybridization to the nucleic acid sequence of the F04 gene (SEQ. ID. NO:1) or the cDNA (SEQ ID NO:3) under stringent conditions as described above.

By using the tools and method described herein, dogs which are genetically normal for the disease (G in both alleles), carriers of the prcd disease (G to A transversion in one allele) and dogs which are affected by (or predisposed to) progressive rod-cone degeneration (G to A transversion in both alleles) can be identified. Upon identification, such affected (or predisposed) or carrier dogs can be eliminated from the breeding stock. Alternatively, dogs which are affected (or predisposed) with prcd, or carriers of the prcd disease, can be mated with genetically normal (without the G to A transversion) dogs to ensure the absence in the litter of dogs affected with prcd.

This invention can be used for any breed of dog including, but not limited to, akita, American cocker spaniel, American eskimos, Australian cattle dog, Australian stumpy tailed cattle dog, basenji, Bernese mountain dog, border collie, Chesapeake bay retriever, Chinese crested, English cocker spaniel, English mastiff, English springer spaniel, Entlebucher mountain dog, Finnish lapphund, German shorthaired pointer, giant schnauzer, Havanese, Labrador retrievers, lowchen, miniature poodle, miniature schnauzer, Nova scotia duck tolling retriever, Portuguese water dogs, samoyed, silky terrier, spitz, standard poodle, standard wirehaired dachshund, Tibetan terriers, toy poodle. Because the identical prcd mutation in the F04 gene has been demonstrated to be present in, and cause PRA in so many different breeds, this mutation appears to have arisen long before the differentiation of the dog population into these different breeds. It is thus expected that the same mutation will prove to be present in other breeds of dogs in which its presence is not currently recognized.

The invention will be further understood by the following examples, which are intended to be illustrative and not restrictive in any way.

EXAMPLE 1

We have produced a retina specific canine EST library from 16 week old beagles. One set of 5 individual overlapping EST clones formed a contig which mapped to the previously specified CFA9 area (Sidjanin et al., 2003) and was therefore further investigated. This sequence contained the later defined F04 exon 8 (see below, EST clone contig, 1085 bp).

From sequence information from the above EST contig, and that of hypothetical human genes located within the corresponding region of the human genome sequence as deposited in GenBank, two primers were designed for RT-PCR: Forward: 5'-caccttgccatgctctggc-3' (located at the end of exon 1)—SEQ ID NO:4 Reverse: 5-aatgcatataaataagcact-tggc-3' (located in exon 8)—SEQ ID NO:5

RT-PCR was performed from a 3.3 week normal dog resulting in a 707 bp product (clone 9) spanning the end of exon 1, exon 2, exon 3, exon 4 and exon 8.

Comparative in silico analysis of canine genomic sequence from our BAC contig (see example 2, below), with public domain human and mouse genomic sequence, identified a highly conserved region, contiguous with the 5' end of clone 9, that included potential CRX binding sites followed by an

ATG translation initiation codon immediately upstream to the sequence of clone 9, and predicted an ORF commencing with this ATG and ending with a stop codon in exon 3. This ORF sequence did not correspond to that of any known gene in Genbank, nor did its putative translation share recognizable domains with or sequence similarity to any other known protein in Genbank.

Because the F04 clone was identified from our retina-specific library, these data combined indicated that the ORF corresponding to F04 represents a novel, previously unrecognized, retina expressed gene. The presence of binding sites for the CRX photoreceptor-specific transcription factor, and the highly conserved structure of the region 5' to the identified start codon identified the putative exon 1 as the first coding exon of a retina-expressed gene. Based on this information a new primer set was designed to include the potential start codon and span exons 1-4:

Forward: 5'-ccagtggcagcaggaacc-3' (5' of exon 1)—SEQ ID NO:6

Reverse: 5'-ccaagccagggcatgagc-3' (3' of exon 4)—SEQ ID NO:7

RT-PCR was performed on both, an 10.4 week normal animal and an 8.6 weeks prcd affected individual resulting in a 562 bp product in both animals (see below, RT-PCR exon 1-4). The only difference observed was a G to A change observed in the affected individual which consequently was identified as the prcd mutation.

To identify the 5' and 3' ends of this gene, we created a 5' RACE retina library from a 10 week old normal dog and a 8 week old affected dog. Amplification of the 5' ends was done with different specific primers located in exon 1 (CCAAG-GTGCTGAGTAGGAAGAGGGTGGTG—SEQ ID NO:8). or exon 3 (AGTCCCTGGGGCCGAGCTCCGCCTGAC—SEQ ID NO:9). Amplification of the 3' ends was done using a specific primer located on exon 1 (CACCACCCTCTTCTACTCAGCACCTTGG—SEQ ID NO:10) which is the exact complement sequence of the specific primer that is used to run the 5' RACE. Seminested PCR was done with a primer located on exon 3 (AGGGACTGGGATCAGCTGGCAGGAGGCAG—SEQ ID NO:11) to verify specificity of the product.

The consensus sequence from these experiments is the clone we consider as the cDNA for the F04 gene (see Seq ID No:3) which is shown in FIG. 2. Details of the cDNA sequence are provided above.

To validate the consensus sequence predicted from the 5' and 3' RACE, two primers were used to amplify the consensus sequence from affected and non-affected retina cDNA.

5' -AGTGGCAGCAGGAACCTCAGG-3' SEQ ID NO: 29

5' -GGATTATATTAGGGATGAATGAGAAG-3' SEQ ID NO: 30

Since the results of a 5' RACE and a 3' RACE are independent results this step is necessary to prove that this transcript is present in the affected and non-affected Retina. The RT-PCR confirmed the presence of such transcript.

By the method described above, the following sequences were obtained.

EST Clone Contig:

The clones originally contained in the EST library produced the following consensus sequence from 5 clones; 1085 bp:

SEQ ID NO: 12
 GAGCAGCTGCAGCAGCTGCCACTGCCCTGTGTACCCACAGGGTGCAAATG
 CCACCACGGGGAGCACCCCGCCATCCCGAAGTGTGTGGCTGTGCAGATG
 CGGGCAGGATGGTCTGGGCACAGGCCTTGGTCCAAGACCAGGCAGGCGT
 GGTACTTGATCTGAGGTGGGCATCATGGCACAGGAGCTGGTCCAGGGGT
 GCCCGGGGACCTTTATAGAACCTCAGTCGGGAAGAAGCCCAAGACCTTGA
 GCCAGAGGGAAGTAATGCTTCTTTGTGAGCCTCAAAGGAGGGAAATGGC
 CAAGGTTTACAGTAATATAATGACACTAATATTATTATTAATAATGGCTA
 ATGTGTCTCAAACGCTTCTTACGTGCTAGGCGCTGTGCCAAGTGCTTTAT
 TTATATGCATTGTCTCATTATGGGGCAGGAAGTGTGTGAGTCTCATT
 ACCCAATAAGGAAAGTGTCTGCTCAAGGTCACCCACAGTGAGTAGTGAAG
 CCAGGACGTGTTCCCGGCAAGGTGATGTAAGCCTGTGAAGGTATTGG
 GCCTCGAGGACATCCTGGGAGTGTGACCTGTCCACCAGGGCACAGGGCAT
 GAGAGCTGGCAACCCCTCCCTGGTGATACTGCCGCTGCTCAGTCTGCAGAA
 ACTCATCATTCCAGGCTGGACCAGACTCTGGGCCCGAGGGCAGTGACCA
 GAGCCACCTTTCCAGGATCTGTATGCTCCTCAGGGAGGAAGCAGTGGCC
 ACTGGCAGGGATGACAGATATCAAGGTTGTCACTCATGCTGCTGTTGCT
 CTGCTGTTTCTCCAACCAGGGGCAGAGCCCTGGGGTAAGGGAGGGTGG
 CAGCCAGCAGCCAGCCAGAGAAGGAGGAGCCAGAGGAGGAAGGCTTTGT
 TGTTTGTTTTACAGGGGGACGGTGCAGGGCTTTAAGGAGGTGGCTTCAA
 GACCTGCTGACTTTAGCCATAAACTGGTACCTAAGGGTCTGGACCTCT
 CTGTGGGATACATATGCCCTTAGTGGGGATTAAGCCTGGAGGGTGGCTG
 AG: AAATTAAGCAAAAAAAAAAAAAAAAAAAAAA

Clone9:

Produced by RT-PCR using primers from exon 8 and the end of exon 1 (707 bp):

SEQ ID NO: 13
 CACCTTGGCCATGCTCTGGCGCCCGGTTCCGCAACCGGGTCCAACCGG
 AGCCAGCGGAGCAGACGGGGCAGTCGTGGGCAGCAGGTCGGAGAGAGAC
 CTCCAGTCTCGGGCAGAAAGGAAGAGCCTCTGAAGTAAGTCTTCACCCG
 GTCAGGCGGAGCTCGGCCCGAGGACTGGGATCAGCTGGCAGAGGCAGTT
 CAAGTCCCGGCTGGCCTCTTACCCACAAAGCATGCTGTGGTGAAGCAGC
 AGCAGCAGCAAGAAGAAAAATGGGAAAAGCAGTCATCAAGAAGGTAGAC
 TCCTCCCTTTGAGTCCCTGGACCTGCCTGGCCTCCCTTTGCCCCAGACCC
 TGGTGGTGGGGCTCCTGAAGCAAGGCTGGCTGGGGCAGGCTGGAGGGCA
 AAGACGCTCATTGCCCTGGCTTGGGCTCCCTTCTCTGAGATCCTGAGGA
 TAGTCTGAGGCAGGCCAGAGAGGACTCAGGTTTCTTATGGAAGGRCTT
 CTCATTATCCCTAATATAATCCTTGCAATGACCCCAAGACCTTGAGCCA
 GAGGGAAGTAATGCTTCTTTGTGAGCCTCAAAGGAGGGAAATGGCCNAG
 GNTTACAGTAATATAATGACACTAATATTATTATTAATAATGGCTAATGT

-continued

GTCTCAAACGCTTCTTACGTGCTAGGCGCTGTGCCAAGTGCTTTATTTAT
 ATGCATT

RT-PCR Exons 1-4

This sequence was created from RT-PCR to compare the ORF of affected and non-affected animals (562 bp):

SEQ ID NO: 14
 CCAGTGGCAGCAGGAACCTCAGGATGGGCAGCAGTGGCTTGTGAGAGCCG
 GCAGGGCCATTTGGCCTTCTCCTGCAGACTCTGTCCGGGAGGGGATGG
 GGCAGCTGAGCCATGTRCACCACCCTCTCCTACTCAGCACCTTGGCCAT
 GCTCTGGCGCCCGGTTCCGCAACCGGGTCCAACCGGAGCCAGCGGAG
 CAGACGGGGCAGTCGTGGGCAGCAGGTCGGAGAGAGACCTCCAGTCTCTG
 GGCAGAAAGGAAGAGCCTCTGAAGTAAGTCTTCACCCGGTCAGGCGGAGC
 TCGGCCCGAGGACTGGGATCAGCTGGCAGAGGCAGTTCAAGTCCCGGCT
 GGCCTCTTACCACAAAGCATGCTGTGGTGAAGCAGCAGCAGCAGCAAG
 AAGAAAAATGGGAAAAGCAGTCATCAAGAAGGTAGACTCCTCCCTTTGA
 GTCCCTGGACCTGCCTGGCCTCCCTTTGCCCCAGACCTGGTGGTGGGGC
 TCCTGAAGCAAGGCTGGCTGGGGCAGGCTGGAGGGCAAAGACGCTCATT
 GCCCTGGCTTGG.

The F04 mutation is bolded and presented as a G in normal and an A in prcd affected dogs.

Splice Variants

In addition to alternative splicing observed in some of the sequences obtained throughout the cloning process of the F04 gene (described above), different splice variants were identified using RT-PCR with primers located in exons 2 and 3, and with primers located in downstream predicted exons (see below).

Clone 1:

RT-PCR was performed using a primer from exon 3 (CAGTCGTGGGCAGCAGGTCGG—SEQ ID NO:15) and one from exon 8 (AATGCATATAAATAAAGCACT-TGGC—SEQ ID NO:16) producing a 316 bp product:

SEQ ID NO: 17
 CAGTCGTGGGCAGCAGGTCGGAGAGAGACCTCCAGTCTCGGGCAGAAAG
 GAAGAGCCTCTGAAGTAAGTCTTCACCCGGTCAGGCGGAGCTCGGCCCA
 GGGTGCCCGGGACCTTTATAGAACCTCAGTCGGGAAGAAGCCCAAGAC
 CTTGAGCCAGAGGGAAGTAATGCTTCTTTGTGAGCCTCAAAGGAGGGAA
 ATGGCCAAGGTTTACAGTAATATAATGACACTAATATTATTATTAATAAT
 GGCTAATGTGTCTCAAACGCTTCTTACGTGCTAGGCGCTGTGCCAAGTGC
 TTTATTTATATGCATT.

Primers from exon 2 (GCAGCAGGTCG-GAGAGAGAC—SEQ ID NO:18) and exon 5 (CTTCCCT-CAGATGTGGAGTCAG—SEQ ID NO:19) were used to amplify cDNA obtained from normal and affected retina. Three different products were obtained as shown below.

Product number 1: SEQ ID NO: 20
 GCCACCGGGTCCACCGGAGCCAGCGGAGCAGACGGGGCAGTCGTGGGCA
 GCAGGTCGGAGAGAGACCTCCAGTCCTCGGGCAGAAAGGAAGAGCCTCTG
 AAGTAAGTCTTCACCCGGTCAGGCGGAGCTCGGCCCCAGGGACTGGGATC
 AGCTGGCAGAGGCAGTTCAAGTCCCGGCTGGCCTCTTACCCACAAAGCAT
 GCTGTGGTGAAGCAGCAGCAGCAGCAAGAAGAAAAATGGGAAAAAGCAG
 TCATCAAGAAGTTTCCAGGGCACTTGCCTCTCCCCGGTCCCAGAGCTCA
 CCCCCTCACCAGCCACTCTGCTGCAGTTCTCAATAAGAAATGCCAGCTGG
 GATCTGTGACATGTCTGCCTGCGGCTGGAAGGAAGCATCTCTCAACCTGT
 CCTCTGAGCGTGTCTGCGTGCCTGTGTGCATGCGTGCCTGTGTTCCAAAG
 GGGCAGTCGCATGTGGGAAGGAAGAAGCCTGACACTTGTCTTGTCAAT
 CTGCTGACTGCTCAGTACCACGGCGGCTCTGCCATTTCTCCCTCACAGTC
 CTGCTCGACCCAGAGCAGAGATCAAAGCAGATTTCCGCTTCTGCTCCCTG
 AGATCCAGGCGCAGACCTGCAGGCAGCTGCTCCCCACTGTCTGGAAGCCA
 TTCATCATGCAAAGCGCCTCCCCACCAAACCCCTGCCTGCACGTGCATCG
 TCCCCCACCATCACCATCCAGCCCCAGGGTGGGCAGGGAGGTCCCTGC
 CTAGCTGCACACCCCCCAGGCCATCAAGAGGCAGGAGATGGGGAGT.

Product number 2: SEQ ID NO: 21
 GCCACCGGGTCCACCGGAGCCAGCGGAGCAGACGGGGCAGTCGTGGGCA
 GCAGGTCGGAGAGAGACCTCCAGTCCTCGGGCAGAAAGGAAGAGCCTCTG
 AAGTAAGTCTTCACCCGGTCAGGCGGAGCTCGGCCCCAGGGACTGGGATC
 AGCTGGCAGAGGCAGTTCAAGTCCCGGCTGGCCTCTTACCCACAAAGCAT
 GCTGTGGTGAAGCAGCAGCAGCAGCAAGAAGAAAAATGGGAAAAAGCAG
 TCATCAAGAAGAGCTCACCCGTACCCAGCCACTCTGCTGCAGTTCTCAA
 TAAGAAATGCCAGCTGGGATCTGTGACATGTCTGCCTGCGGCTGGAAGGA
 AGCATCTCTCAACCTGTCTCTGAGCGTGTCTGCGTGCCTGTGTGCATGC
 GTGCGTGTGTTCCAAAGGGCAGTCGCATGTGGGAAGGAAGAAGCCTGA
 CACTTGTCTTGTCAATCTGCTGACTGCTCAGTACCACGGCGGCTCTGCC
 ATTTCTCCCTCACAGTCTGCTCGACCCAGAGCAGAGATCAAAGCAGATT
 TCCGCTTCTGCTCCCTGAGATCCAGGCGCAGACCTGCAGGCAGCTGCTCC
 CCACTGTCTGGAAGCCATTATCATGCAAAGCGCCTCCCCACCAAACCC
 TGCTGCACGTGCATCGTCCCCCACCATCACCATCCAGCCCCAGGGTG
 GGCAGGGAGGTCCCTGCCTAGCTGCACACCCCCCAGGCCATCAAGAGGCA
 GGAGATGGGGAGT.

Product number 3: SEQ ID NO: 22
 GCCACCGGGTCCACCGGAGCCAGCGGAGCAGACGGGGCAGTCGTGGGCA
 GCAGGTCGGAGAGAGACCTCCAGTCCTCGGGCAGAAAGGAAGAGCCTCTG
 AAGTAAGTCTTCACCCGGTCAGGCGGAGCTCGGCCCCAGGGACTGGGATC
 AGCTGGCAGAGGCAGTTCAAGTCCCGGCTGGCCTCTTACCCACAAAGCAT
 GCTGTGGTGAAGCAGCAGCAGCAGCAAGAAGAAAAATGGGAAAAAGCAG

-continued

TCATCAAGAAGTCCTGCTCGACCCAGAGCAGAGATCAAAGCAGATTTCCG
 CTTCTGCTCCCTGAGATCCAGGGCAGACCTGCAGGCAGCTGCTCCCCAC
 5 TGTCTGGAAGCCATTATCATGCAAAGCGCCTCCCCACCAAACCCCTGCC
 TGCACGTGCATCGTCCCCCACCATCACCATCCAGCCCCCAGGGTGGGCA
 GGGAGGTCCCTGCCTAGCTGCACACCCCCCAGGCCATCAAGAGGCAGGAG
 10 ATGGGGAGT.

RT-PCR was done on affected and non-affected retina using the following primers:

15 5' - TTAATCAGTCTGCACAAGGTCG - 3' SEQ ID NO: 31
 5' - GGGTCATTGCAAGGATTATATTAGG - 3' SEQ ID NO: 32

20 Two splice variants were observed:

Product number 1: SEQ ID NO: 33
 25 TTAATCAGTCTGCACAAGGTCGGGTTGGCTGACCCCACTAATCAGCTTGA
 GCCTCCTAATCCAGTGGCAGCAGGAACCTCAGGATGGGCAGCAGTGGCTT
 GTGAGAGCCGGCAGGGCCATTTTGGCCTTTCTCCTGCAGACTCTGTCCGG
 30 GAGGGGATGGGGCAGCTGAGCCATGTRCACCACCCTCTTCTACTCAGCA
 CCTTGGCCATGCTCTGGCGCCCGGTTTCGCCAACCGGGTCCAACCGTGA
 GAAGCTGATGGGGCCATGGGCAGGGATGGGGAGAGAGGAGAAGCTAGGGG
 35 GTGAGGGGTGGTGCAGGGGCTGCCTGGACCTCCTGGGAGGCTGGAGGGCG
 GGGAGGATTTGCAGGGAGGTCCAGAGAGGTTTCCATCAGAGCACGCGGG
 GCGGGGGCTCGCAGGTGCTCCGAGACTGGCTGGAGTCCCCGGTCCCCCA
 40 GCCAACACGGCCAGGAGAGGGGTTCTGGGCCCGGGCGCTGCCACAGC
 TCTTCCAGCCTCTTCTCCCGCCACAGGGAGCCAGCGGAGCAGACGGG
 GCAGTCGTGGGCAGCAGGTCGAGAGAGACCTCCAGTCTCGGGCAGAAA
 GGAAGAGCCTCTGAAGTAAGTCTTCACCCGGTCAGGCGGAGCTCGGCCCC
 45 AGGGACTGGGATCAGCTGGCAGAGGCAGTTCAAGTCCCGGCTGGCCTCTT
 ACCCACAAAGCATGCTGTGGTGAAGCAGCAGCAGCAGCAAGAAGAAAA
 TGGGAAAAAGCAGTCATCAAGAAGGTAGACTCCTCCCTTTGAGTCCCTGG
 50 ACCTGCCTGGCCTCCCTTTGCCCCAGACCCTGGTGGTGGGGCTCCTGAAG
 CAAGGCCTGGCTGGGGCAGGCTGGAGGGCAAAGACGCTCATTGCCCTGGC
 TTGGGCTCCCTTCTCTGAGATCCTGAGGATAGTCTGAGGCAGGCCCAGA
 55 GAGGGACTCAGGTTTCTTATGGAAGGGCTTCTCATTATCCCTAATATAA
 TCCTTGCAATGACCC

Product number 2: SEQ ID NO: 34
 60 TTAATCAGTCTGCACAAGGTCGGGTTGGCTGACCCCACTAATCAGCTTGA
 GCCTCCTAATCCAGTGGCAGCAGGAACCTCAGGATGGGCAGCAGTGGCTT
 GTGAGAGCCGGCAGGGCCATTTTGGCCTTTCTCCTGCAGACTCTGTCCGG
 65 GAGGGGATGGGGCAGCTGAGCCATGTRCACCACCCTCTTCTACTCAGCA

- continued

CCTTGGCCATGCTCTGGCGCCGCCGGTTCGCCAACCGGGTCCAACCGGAG

CCCAGCGGAGCAGACGGGGCAGTCTGTGGGCAGCAGGTCCGAGAGAGACCT 5

CCAGTCTCTGGGCAGAAAGGAAGAGCCTCTGAAGTAAGTCTTACCCGGT

CAGGCGGAGCTCGGCCCCAGGGACTGGGATCAGCTGGCAGAGGCAGTTCA

AGTCCCGGCTGGCCTCTTACCCACAAAGCATGCTGTGGTGAAGCAGCAG 10

CAGCAGCAAGAAGAAAAATGGGAAAAAGCAGTCATCAAGAAGGTAGACTC

CTCCCTTTGAGTCCCTGGACCTGCCTGGCCTCCCTTTGCCCCAGACCCCTG 15

GTGGTGGGGCTCCTGAAGCAAGGCCTGGCTGGGGCAGGCTGGAGGGCAA

GACGCTCATTGCCCTGGCTTGGGCTCCCTTCTCTGAGATCCTGAGGATA 20

GTCTGAGGCAGGCCAGAGAGGGACTCAGGTTTCTTATGGAAGGGCTTCT

TCATTCATCCCTAATATAATCCTTGCAATGACCC

The above results indicate that there are several retinal splice variants of F04. Based on these splice variants and comparative genomic analysis, the genomic organization of F04 was characterized. However, all splice variants relevant

to prcd include exons 1-4 and the shortest and most abundantly expressed such disease-relevant transcript is the cDNA identified as SEQ ID No:3.

EXAMPLE 2

Since mapping the prcd locus to canine chromosome 9 (CFA9), we have mapped the prcd disease interval at higher resolution, narrowed the identified canine genomic region in which the prcd gene is located, and tested all candidate genes within that region. Initially, we created a physical map of the region using canine BACs (Sidjanin, 2003), and identified multiple polymorphic markers within and flanking this region. Examination of genotypes of prcd-affected dogs from multiple breeds for these polymorphic markers established that within breeds the haplotype that cosegregated with the prcd mutation extended across a broad region, including the physically mapped interval (Sidjanin et al., 2003). However, comparison of these genotypes revealed that the breed specific haplotypes varied among breeds within the area initially published (Sidjanin et al., 2003), but was consistent for all breeds for a set of markers physically located within a single BAC clone (BAC #10M13; Li et al, 1999) located adjacent to the area initially published. This BAC clone contained several genes. Single nucleotide polymorphisms were identified for each of these genes, and a single haplotype was constructed which differentiated the prcd-transmitting CFA9 from that of all normal dogs tested (Table 1) in all breeds known to be affected with prcd.

TABLE 1

Linkage disequilibrium (LD) region flanking the canine prcd/F04 gene on canine chromosome 9 (CFA9). All genes in this region are located in canine BAC# 10M13.

Poly-morphism #	Polymorphism Name	Affected allele	Alternative allele	Polymorphism Location
1		A	G	FLJ22341
2	p43	G	T	FLJ22341
3		C	T	FLJ22341
4		C	T	FLJ22341
5	b712	A	C	FLJ22341
6	b817	deletion	CTG	FLJ22341
7	b1149	T	C	FLJ22341
8	p49	C	T	FLJ22341
9		T	G	FLJ22341
10	SINE	no SINE	SINE	FLJ22341
11	p48	G	A	FLJ22341
12		A	G	FLJ22341
13		A	G	FLJ22341
14		T	C	FLJ22341
15		C	T	FLJ22341
16	p45	T	C	FLJ22341
17	p41	C	T	FLJ22341
18		C	T	FLJ22341
19	b682	C	G	FLJ22341
20	b937	A	G	FLJ22341
21	b1130	A	G	FLJ22341
22	b1275	G	deletion	FLJ22341
23	b1351	G	A	FLJ22341
24	p38	T	C	CYGB
25		G	A	CYGB
26		A	G	CYGB
27	CYGB	T	C	CYGB
28	b3128	T	C	CYGB
29	b3133	T	C	CYGB
30	b3605	C	G	CYGB
31	b3769	C	G	CYGB
32	3820-23	deletion	TGCC	CYGB
33	p40	A	G	CYGB
34		G	A	CYGB

TABLE 1-continued

Linkage disequilibrium (LD) region flanking the canine
prcd/F04 gene on canine chromosome 9 (CFA9). All genes
in this region are located in canine BAC# 10M13.

Poly- morphism #	Polymorphism Name	Affected allele	Alternative allele	Polymorphism Location
35		A	G	CYGB
36	31F5	A	C	CYGB
37	31F4	A	G	CYGB
38		A	G	
39	285	C	T	F04
40	851	C	G	F04
41	999	C	T	F04
42	1298	A	G	F04
43	1633-1635	CTT	deletion	F04
44	1854	deletion	C	F04
45	1912	C	G	F04
46	2413	A	G	F04
47	2590	T	C	F04
48	2601-2603	deletion	TCC	F04
49	2607	A	G	F04
50	2660-2666	ATGAGAA	deletion	F04
51	2710	C	T	F04
52	2741	G	A	F04
53	2769	C	T	F04
54	3119	G	A	F04
55	3804	C	T	F04
56	3971	G	C	F04
57	4459	G	A	F04
58	5244	G	A	F04
59	5698	G	T	F04
60	6254	A	C	F04
61	6318	deletion	G	F04
62	6953	T	C	F04
63	7030	T	A	F04
64	7183	A	C	F04
65	7239	G	A	F04
66	7855	A	G	F04
67	8230	C	T	F04
68	8843	G	deletion	F04
69	8977	G	A	F04
70	10230	A	G	F04
71	10268	A	C	F04
72	10855	A	T	F04
73	12175	A	G	F04
74	12613	A	G	F04
75	15033	C	T	F04
76	15347	G	A	F04
77	15359	A	T	F04
78	15445	T	C	F04
79	17200	T	C	F04
80	17407	deletion	C	F04
81	17435-17437	GGG	deletion	F04
82	17672	T	deletion	F04
83	17892	A	G	F04
84	b1409	C	T	STHM
85	p2	A	C	STHM
86	STHM-NaeI	A	G	STHM
87	STHM- AvaI	C	T	STHM
88	base 3526	C	T	STHM
89	base 3655	G	A	STHM
90	10-299	G	A	STHM
91	10-597	G	G	STHM
92	b2263	deletion	T	STHM
93	b2411	T	C	STHM
94	b2425	deletion	C	STHM
95	b2748	G	deletion	STHM
96	from RT-PCR	A	G	STHM

The "affected allele" for each polymorphism is that found on all examined pred-transmitting chromosomes from dogs of multiple breeds; the "alternative allele" is that which is present, for example, in BAC # 10M13. Where polymorphism information is bolded, the Polymorphism Name indicates the position (base number) in the F04 genomic sequence (i.e. SEQ ID NO: 1). Polymorphism Location indicates the gene in the genomic sequence of which the polymorphism is located.

For each of these genes the exons were sequenced and examined, and a disease associated sequence change (i.e. a mutation) was found in only one gene. This gene, referred to herein as F04, is located within the interval described in U.S. Pat. No. 5,804,388. Details of the canine cDNA and genomic DNA sequence for F04 have been provided above. The mutation, at nucleotide 1298 of SEQ ID NO: 1 represents a G to A transition, from normal sequence to affected. We refer to this sequence change as the “prcd mutation” in F04 gene herein and is shown as polymorphism no. 42 in the table above.

EXAMPLE 3

This example describes a PCR-based restriction enzyme digestion test developed to identify the sequence change in the F04 gene. The following primers were used:

primer 1: ccagtgccagcaggaacc—SEQ ID NO:27

primer 2: ccgacctgctgccacgactg—SEQ ID NO:28

PCR is run under standard conditions (annealing temp 58 degree C., 1.5MgCl₂) in 25 microliters, 35 cycles. The amplification product is 512 bp in size (corresponding to bp 1182 to 1693 in SEQ ID NO:1. The restriction enzyme RsaI digests the amplification product bearing the A allele, but not the G allele. Conversely, ApaLI digests the G allele but not the A allele. Both digests were performed at 37° C. for 2 hours.

Restriction digestion thus yields the diagnostic results shown in Table 2:

TABLE 2

ENZYME (restriction site)	ALLELE	FRAGMENT SIZE(S) (bp)
RsaI (GTIAC)	G	512
	A	116; 396
ApaLI (G TGCAC)	G	115; 397
	A	512

A large population of dogs affected with prcd was examined. We have tested more than 100 affected animals from 13 different breeds or breed varieties. These include: 36 Australian cattle dogs, 2 Chinese crested, 5 English cocker spaniels, 5 Finish Laphunds, 48 Labrador retrievers, 45 miniature or toy poodles, 1 Nova Scotia duck tolling retriever, 3 Portuguese water dogs, 1 Silky Terrier, 25 American eskimos, and 14 Entlebucher mountain dogs.

An example of the identification of the G allele (normal) and the A allele (affected allele) following RsaI digestion is shown in FIG. 3A and following digestion with ApaLI is shown in FIG. 3B. For the RsaI digestion (FIG. 3A), a normal dog (GG) shows a product of 512 bp, an affected dog (AA) shows products of 396 bp and 116 bp while a carrier dog (AG) shows products of 512 bp, 396 p and 116 bp. For the ApaLI digestion (FIG. 3B), a normal dog (GG) shows products of 397 bp and 115 bp, an affected dog (AA) shows a product of 512 bp, and a carrier dog (AG) shows products of 512 bp, 397 bp and 115 bp. Thus, this method can be used for identification of normal dogs (i.e., in which both alleles of the F04 gene have G as the nucleotide at a position corresponding to nucleotide position 1298 of SEQ ID NO:1), carrier dogs (i.e., in which one allele has G and the other allele has A as the nucleotide at a position corresponding to nucleotide position 1298 of SEQ ID NO:1) and affected or predisposed dogs (i.e., dogs in which both alleles of the F04 gene have A as the nucleotide as a position corresponding to nucleotide position 1298 of SEQ ID NO:1).

EXAMPLE 4

To confirm the exclusion of the affected allele from the general dog population, we tested 1,000 animals from 67 breeds not known to have the prcd form of PRA, to establish the absence of the “A” allele. These dogs were tested by Pyrosequencing (Biotage, Charlottesville, Va.; <http://www.pyrosequencing.com/DynPage.aspx>, Fakhrai-Rad et al., 2002; Ronagi et al., 2002; Shendure et al., May 2004) as follows. The technique is based on the amplification of the target sequence with an unlabeled forward primer and a biotin labeled (5'Bio) reverse primer, which are used to isolate a single stranded DNA product. A sequencing primer is used to start a subsequent nucleotide specific primer extension and presence or absence of a nucleotide is recorded in an allele frequency dependent manner based on a luciferase reaction.

Forward primer: 5' TTGTGAGAGCCGGCAGG3' SEQ ID NO: 23
Reverse primer: 5' **Bio**/ATGGCCAAGGTGCTGAGTAG3' SEQ ID NO: 24
Sequencing primer: 5' GGGG CAGCTGAGCCA3' SEQ ID NO: 25

Product: 113 bp (primer sequence is shown in capital letter, the G/A polymorphism is bolded, and Bio indicates the biotin label:

TTGTGAGAGCCGGCAGGggccatttg-gcctttctctgcagactctgtccgggaggggatGGGGCA GCTGAGC-CAtgtg/acaccacctcttcCTACTCAGCACCTTGGCCAT—Bio—SEQ ID NO:26 FIG. 4 illustrates the test set-up for the procedures of this example. Based on the test sequence, a series of nucleotides is injected one at the time during the primer extension (the sequence is shown on the bottom of each panel) and the resulting light reaction is registered (indicated by the bar for each nucleotide, directly proportional to the amount of alleles present). Nucleotides one (C) and 7 (G) of the sequence are negative controls and should not produce any light reaction. Positions 2, 3, 4, 8 and 9 are positive controls and react the same in all samples based on the tested sequence. The mutation in question corresponds to nucleotides 5 and 6. In normal animals, only the G allele is present and produces a reaction of the same strength as the positive controls. In affected individuals the same is true for the A allele, while carriers have both alleles at a 50/50 ratio and, therefore, produce half the intensity at each position. In all cases, the animals tested by Pyrosequencing™ were “GG”, i.e., they had G in both alleles of the F04 gene at a position corresponding to position 1298 of SEQ ID NO:1.

It will be appreciated by those skilled in the art that routine modifications can be made to the various embodiments described above. Such modifications are intended to be within the scope of the present invention.

REFERENCES

1. Aguirre, G. D.: Inherited Retinal Degenerations in the Dog Trans. Amer. Acad. Ophth. and Otol. 81: 667, 1976.
2. Aguirre G D, Acland G M. Variation in Retinal Degeneration Phenotype Inherited at the prcd Locus. Exp. Eye Res. 46: 663, 1988
3. Acland G, Fletcher R T, Gentleman S, Chader, G. and Aguirre, G: Non-allelism of Three Genes (rcd1, rcd2 and erd) for Early-Onset Hereditary Retinal Degeneration. Exp. Eye Res. 49: 983, 1989.

- 4 Aguirre, G. and Acland, G.: Inherited Retinal Degeneration in the Labrador Retriever Dog. A New Animal Model of RP? Invest. Ophthalmol. Vis Sci. (Supp). 32(4), 1991;
5. Acland, G., Ray, K., Mellersh, C., Gu, W., Langston, A., Rine, J., Ostrander, E., and Aguirre, G. Linkage analysis and comparative mapping of canine progressive rod-cone degeneration (prcd) establishes potential locus homology with retinitis pigmentosa (RP17) in humans. Proc. Natl. Acad. Sci. USA. 95:3048-3053, 1998.
6. Fakhrai-Rad, H., Pourmand, N., Ronaghi, M. Pyrosequencing: An accurate detection platform for single nucleotide polymorphisms. Human Mutation, 2002; 19(5).
7. Kijas, J. W., Cideciyan, A. V., Aleman, T. S., Pianta, M. J., Pearce-Kelling, S. E., Miller, B. J., Jacobson, S. G., Aguirre, G. D., and Acland, G. M. Naturally-occurring rhodopsin mutation in the dog causes retinal dysfunction and degeneration mimicking human dominant retinitis pigmentosa Proc. Natl. Acad. Sciences USA 99:6328-6333, 2002.
8. Li, R., Mignot, E., Faraco, J., Kadotani, H., Cantanese, J., Zhao, B., Lin, X., Hinton, L., Ostrander, E. A., Patterson, D. F., et al. 1999. Construction and characterization of an

- eightfold redundant dog genomic bacterial artificial chromosome library. Genomics 58: 9-17.
9. Pearce-Kelling, S. E., Nickle, A., Kijas, J. W., Sidjanin, D. J., Miller, B. J., Aguirre, G. D. and Acland, G. M. 2002.
10. Ronagi M, Elahi E. Discovery of Single Nucleotide Polymorphisms and mutations by Pyrosequencing. Comp Funct Gemon. 2002; 3: 51-56.
11. Shendure J, Mitra R D, Varma C, Church G M. Advanced sequencing technologies: methods and goals. Nature Reviews Genetics, May 2004; 5(5), 335-344.
12. Sidjanin, D. J., Miller, B., Kijas, J. K., McElwee, J., Pillardy, J., Malek, J., Pai, G., Feldblyum, T., Fraser, C., Acland, G. and Aguirre, G. Radiation Hybrid Map, Physical Map and Low-Pass Genomic Sequence of the Canine prcd Region on CFA9, and Comparative Mapping with the Syntenic Region on Human Chromosome 17. Genomics 81:138-148, 2003.
13. Zhang, Q., Acland, G. M., Wu, W. X., Johnson, J. L. Pearce-Kelling, S., Tulloch, B., Vervoort, R., Wright, A. F., Aguirre, G. D. Different RPGR exon ORF15 Mutations in Canids Provide Insights into Photoreceptor Cell Degeneration Hum. Molec. Genet. 11:993-1003, 2002.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 34

<210> SEQ ID NO 1

<211> LENGTH: 18592

<212> TYPE: DNA

<213> ORGANISM: canis familiaris

<400> SEQUENCE: 1

```

cggccagggtg gcacctctga ctcccagccc aaacctgatg ccagtggtcca      50
cttctccctg tcgctccctc ggcaccccgc cttctcaag acttggtgtc      100
cctctgcaag tgtgagaaga ggtcggctca cctctccgc tttggcttat      150
gtattttaaa aatcgttttt caaagtagag agcccagggtg cagccccagc      200
tctggccctc cctgggagcc tgggcaggag accccttgac accgcttcca      250
tctccttgga ggggaaggaaa atctagtgca gaccyctggg gtttttgag      300
agggctggag gaagctggat gctcagacct ctgtgtgctc cacatgctgc      350
ctgggccacc tcaactgaacc cctctgacag gacacccgat gcctgtgcgg      400
tgcccttcca agtggctgct cagaagcttt gcaactgggaa agcaagtatt      450
cgctatttct atttagtatt tctatttagc tttatctcat cttttacaag      500
tcttatgtgt gtttattatg caggactgta ttcgcacaga tgtggaagat      550
ctaatgatg agcagatgca tatacttatt tcatgagtgc acacttaaat      600
ccagtctttt atggaagggg ctatggaaat cagtaacatt tggggaggac      650
tgtccagagg ggagaacaca actgctcagc cgcccccca ctccccggcc      700
tccctgtct tctggcttc attatctaat attcttctc ccctccccat      750
ggctctccat gacatcattg ttctgccaac actcaacttc cagttgctgg      800
aacatgctct gtgcttttgt gtcagccgcc ccggaagagt cttctgttgg      850
sggggaggta accttccttg aacacctgca aattccaatg cccccagctc      900
ctctcccaag cattccctga cacatgcaac tccgaaagtg ctctgcgggt      950

```

- continued

gcctctcacc	acccaagtcg	ctctactgtg	gtcattaatg	tgacttgcy	1000
gctcaagtgt	ctagactaga	agccccttga	gggttaggcc	caggtcctag	1050
tcacatctgt	atccagaatg	gacagcttga	ttaccctgc	caccgcaggc	1100
gacaacttgg	gcccagtgag	gttaatcagt	ctgcacaagg	tcgggttggc	1150
tgacccact	aatcagcttg	agcctcctaa	tccagtggca	gcaggaacct	1200
caggatgggc	agcagtggct	tgtgagagcc	ggcaggcca	ttttggcctt	1250
tctcctgcag	actctgtccg	ggaggggatg	ggcagctga	gccatgtrca	1300
ccaccctctt	cctactcagc	accttggcca	tgtctggcg	ccgccggttc	1350
gccaaccggg	tccaaccgtg	agaagctgat	ggggccatgg	gcaggatgg	1400
ggagagagga	gaagctaggg	ggtgaggggt	ggtgcagggg	ctgcctggac	1450
ctcctgggag	gctggagggc	ggggaggatt	tgacggagg	tccagagagg	1500
tttcccatca	gagcacgcgg	gggcgggggc	tcgaggtgc	tccgagactg	1550
gctggagtcc	ccggtcccc	agcccaacac	ggccaggaga	gggggttctg	1600
ggcccgggcg	ctgccacag	ctcttcagc	ctcttcctcc	cgccacagg	1650
gagcccagcg	gagcagacgg	ggcagtcgtg	ggcagcaggt	cggagagaga	1700
cctccagtcc	tcgggcaggt	aaggcagagt	ctgggctggg	ggaggcaggg	1750
tgcgtcgagg	aagcggctgc	cctggccgcc	ccgaccgtgc	ctgggcaggt	1800
acatgagtgc	acccgagccg	gcgcgccggg	gccctcgcc	ccagccacc	1850
ggtccccgtg	tgcccgggtg	gcagcctcgg	tgtctgtgct	cccccgggc	1900
actgggcgcc	csggcctgtc	ctctgcaccg	cagctgctct	gctttgccc	1950
agtgcggggg	ggtcccccg	gtcccatcgg	aaggcgcggg	gggaccggag	2000
aggatggggc	aggagcagct	ccgggcggcc	ggctcgctgc	ccttccccct	2050
ccccgcggcc	cccgtccgc	ctcagccgct	ccctgcccc	ggccgcggc	2100
gggattcgcc	caccggcccc	caataggagg	cgcaggagcg	gcatgacgtc	2150
atcggcaccg	cctgccattg	gctgggcagc	tctgcgggc	aggctcgctg	2200
ctccagcggc	cgaaagttaa	ctcttcctta	ggccgaagcc	atgtggctcc	2250
acaagggggg	aagtttgggg	aacttctgga	ttcttccttc	cctgggtgac	2300
cagtgtcctt	tgatgttagg	ggctcctatg	cccaacaaac	cacggaaaaa	2350
tcaacatgca	tttattaaga	acataccggt	gtgcgtgttc	ttttgtgccc	2400
ccggaccac	ctrgtggggg	agtcctgtgt	gaaggacat	tctctcctgc	2450
aaaaggctca	ctagccttct	ctcaactcta	gtgagacaaa	gcacatgatg	2500
cccttgggct	ccggggcctg	tggctggagg	gagtctcccc	acagcgtca	2550
gatggctgag	ccagtgagcg	tgctgcctg	ctggggcacy	ccaccggctc	2600
tctccrggt	gtgtaggacc	tgctgggtg	ccctcagcc	atgtggagac	2650
tggcgagcca	tgagaaatga	gaatgggaat	ctgtctccgt	atgcccggcc	2700
aaatcctcy	tcggtgctgg	gattcctcca	agctctgaat	rtcaggaggg	2750
cagccctggg	catgtgccyg	agacaggtat	ttctgggcca	cccttcttgc	2800
acaatctagg	ctagctgaga	tggctcatgat	actaccaag	taggcctgct	2850
ggtgaaatgg	gctgacaaa	gtgaaatgat	gagcactggg	cctcacgcag	2900
agcaggccct	tgaatgacta	gtcctccctg	ttgagtttgg	gtctggaggc	2950

-continued

ggacagccag agtccacatc ctgactccct gcttccctgac cgagagcctc	3000
tgggaaagct atgtgatctt tctatcttga tataaactgg gattaataac	3050
agaatgggtg ggggggtgtt gtgaggttca aattgagatc atcctaaagc	3100
acttggcacg aaacagctrt ttaataaatg ccggctagct attctcctgt	3150
tgttacctgg ctcttgatca gtgttctatt ctcccttga ggtctcttaa	3200
acgttaactc acttggaggt tgtaacagcc ccagaggggt ggcaagacaa	3250
gtgtttctat ctcttgtaa tgggtggagga aactgagggg aggggagggc	3300
tcagtttttc actcagagtc atccatccta tttgtggctg atggcaactg	3350
acttcaggta gtcggctctc tctacatgaa atgggcctgg accctcctg	3400
tcaggagaaa aaagctgaat ctggaccatc tggcccagcc tcgtggggtc	3450
tagccagaag gaagcagtg cctgttaact cccagggacc cagttaactg	3500
gaaaaatcag cctaaccatc aacacctcct gcttcgggtg gctgttgtga	3550
agggtgggtc tggggagcag taggcatgac atctctgctc tgcaattcca	3600
cagtcacaaa ttcagctga tttcctggct gctcctacc ctcagtagtg	3650
gggtgcctcc ctaggcgtgg ggcaaagggg agaagtctgg aaagacggga	3700
aggacgtccc cttcaatcct ctgactccca tgcttttctg tttagaaagg	3750
aagagcctct gaagtaagtc ttcacccggg caggcggagc tcggccccag	3800
ggaytgggat cagctggcag aggcaggtag ggcagggctg caagccttg	3850
aaggtagagg gctgggctgg ggacaaggca ggctctgcaa ggctggcca	3900
tgaggagca gagctccatg gagggtagac agaaggcggg tggcctctca	3950
tcagctcctg cctcaagcct sctgtggctc aggcctagc gcaaggcttt	4000
gttagtttta agggaaggc gtgtggtgaa gtgtggtca tgctggcact	4050
gtagtccag aggacttcta agggagaggg tgtgctctgg aatatcatt	4100
ctgcaatgca agccccctg ttgggatggg aggaagtgcc aatctggttt	4150
tctatctcag ttcaagtccc ggctggcctc ttaccacaaa agcatgctgt	4200
ggtggaagca gcagcagcag caagaagaaa aatgggaaaa agcagtcac	4250
aagaaggtag actcctcct ttgagtcctt ggacctgctt ggcctcctt	4300
tgcccagac cctgggtgtg gggctcctga agcaaggcct ggctggggca	4350
ggctggaggg caaagacgt cattgccctg gcttgggctc ccttcctctg	4400
agatcctgag gatagtctga ggcaggccca gagagggact caggtttctt	4450
atggaaggrc ttctcattca tccctaatat aatccttgca atgaccaag	4500
aagactgggc gtgttattat ccacactttt ggaaatgagg aaacagagag	4550
aggtaagga atctgtccag tgtcatccag ctagttaatc ctgccccca	4600
ccccaccca cccccgccc tcccagcctc ctttgagggc tgcaagccc	4650
acactcttac ccaccagggc acaggcctct ctgaaatcac ctggaagttt	4700
gcagcttgca gctgctatgt gagagcaggg gttccacggg cccggcagcc	4750
ccaaagcctg tggccaagg ctgtgtggta tcagtttgc atgggtggcg	4800
tctagtttcc agggcacttg cctctccccg gtccccagag ctcacccct	4850
caccagccac tctgctgcag ttctcaataa gaaatgccag ctgggatctg	4900

- continued

tgacatgtct	gcctgcggct	ggaaggaagc	atctctcaac	ctgtcctctg	4950
agcgtgtctg	cgtgcctgtg	tgcattgcgtg	cgtgtgttcc	aaaggggag	5000
tcgcatgtgg	gaaggaaga	agcctgacac	ttgttcttgt	caatctgctg	5050
actgctcagt	accacggcgg	ctctgccatt	tctccctcac	agtctctctc	5100
gaccagagc	agagatcaa	gcagatttcc	gcttctgctc	cctgagatcc	5150
aggcgcagac	ctgcaggcag	ctgctcccca	ctgtctggaa	gccattcatc	5200
atgcaaagcg	cctccccacc	aaaccctgc	ctgcacgtgc	atctcccc	5250
caccatcacc	atccagcccc	caggggtggc	agggaggtcc	ctgcctagct	5300
gcacaccccc	caggccatca	agaggcagga	gatggggagt	tctctcgaca	5350
gcagcctgtc	tgccgcctg	actccacatc	tgagggaagg	aaggaaagg	5400
tgagatgcca	cagacagagg	ggaccacgct	gaagccatgg	gggaggggct	5450
gctgatcttg	ccctggaagc	ctctagaagt	aggcagggg	ggaggcagg	5500
gaagggtaa	accaggggaa	ggagctgtgc	gctggaatgg	cgacagagcc	5550
ccaccgcca	ctcgacatgg	gccaggagtt	cgtgaccacc	tgtctcagct	5600
cctgtcagcc	tgtctttctc	ctgcgaggtg	ttggccttcc	ttggtgacag	5650
ggctgtcggg	ctgagggcca	ggggcaccgt	tcttggggcc	cccatctkcg	5700
tccccgagcc	cacctgtgta	ttcatcctct	aatctgtttg	ccatgctcct	5750
gtcacttcag	cctcggctct	gctctctacc	atttccacgt	tgctgcctc	5800
cttgcaactag	tctgaggaat	tgtcaggcca	aggcaccctg	gctggacagg	5850
ggctggccca	cggcccagac	acacctccac	gaggcgacac	cccttcgctg	5900
caactgttcta	gggacctgct	caggagagg	tggtcctct	gggctcggg	5950
cccagagggg	aggagagaag	gggaagggaa	gggctgctgg	cgatgggggg	6000
actgtgtcgg	ctggccttgg	cggttgccc	ggccctggca	gctgggggtg	6050
catgtgggct	gggcccggag	ggccctctcc	cccagggagc	aggctggctt	6100
cgggtgggagc	agattgtgtt	tacaccttcc	ccacacacc	agcccacgct	6150
cgctcttat	tccccgggac	tctcccacc	ctgggctctc	tctgcaccac	6200
gggcacgttt	gcagctcctc	tcttctgca	ggaagttgcc	gccctcagca	6250
gagmgctcct	ctacagaagg	ctgccagggc	ccaggcgtc	cctcctcggc	6300
ccactatctc	ccgtcgtggg	gggggaccca	gtgtcccaa	gaggctgaat	6350
ccaccacacc	cccatttct	tggaaaacag	ctgctgcttg	ggaatggggg	6400
caggaaggaa	agcccggggg	gcttggcaga	cttgaccata	ataggaggga	6450
agggattaag	ggcaaccaga	gagagagggc	cgagagagcc	ggggcgcctc	6500
tggtctcagg	gtgcatgaga	taatgtagaa	tttaagctcg	gggagtccag	6550
ctccaagctc	tggattttaa	tcttgactcc	accatcactt	tccagttctg	6600
tggcctcggg	tgggttactg	aatgtaaacc	tgtctcagag	ttgtaagggt	6650
taaattagat	aatgggtata	aagtgtctcg	cgcacttagt	aagcacgcag	6700
tatatctgag	cccaggggtg	ggggacagtg	tttgtgagct	gtcagccact	6750
gaacaactgg	tcactttgca	acaaccgtag	gttcagaaca	gctagtcctt	6800
tacctctca	ccccatggcc	cttctgccc	tgtctttcca	catacacaac	6850
agcaggggta	tgggcagttc	tggaaacaac	cagagcccag	cacaggggca	6900

- continued

cctggtagga	cccagcacc	gggaaggctg	gacgatggag	caccacgggt	6950
gcytctgggt	gcctggaacc	ctgtccccac	ctccagtggg	agtcctgacc	7000
tggacatctt	ccctccaact	ggctctgcgw	ccccaaatga	atctcagctc	7050
ctagagaaga	caggaggcca	tggccctggg	gcctttatgg	tcctctgtct	7100
gaatgcta	ctctttactg	gctggagcct	gagtgcacagg	gaaaaggcgg	7150
ttctgagctg	cagggtggcc	gagggcggca	ggmaggagca	gggaggtgct	7200
gttgctgct	acttctgtgg	ctgctgccag	tctctcctrg	agatgggaac	7250
atgaccagag	agctaagag	gtggcggggg	tgggggtggg	ggagaaaggg	7300
aggcagacgg	agcagctgca	gcagctgcc	ctgccctgtg	tcacccaggg	7350
gtgcaaatgc	caccacgggg	agcaccgcc	ccatcccgaa	ctgtgtggct	7400
gtgcagatgc	gggcaggatg	gtcctgggca	caggccttgg	tccaagacca	7450
ggcaggcgtg	gtacttgatc	tgaggtgggc	atcatggcac	aggagctggt	7500
cccaggggtg	cccggggacc	tttatagaac	ctcagtcggg	aagaagccca	7550
agaccttgag	ccagagggaa	gtaatgcttc	ttgtgagcc	tcaaaaggag	7600
ggaaatggcc	aaggtttaca	gtaatataat	gacactaata	ttattattaa	7650
taatggctaa	tgtgtctcaa	acgcttctta	ctgcttaggc	gctgtgccaa	7700
gtgctttatt	tatatgcatt	gtctcattta	tggggcagga	actgttgtca	7750
gtctcattta	ccaataagg	aaagtgcttg	ctcaaggtea	cccacagtga	7800
gtagtgaagc	caggacgtgt	tccccggcaa	ggtgatgtaa	aagcctgtga	7850
aggtrttggg	cctcgaggac	atcctgggag	tgtgacctgt	ccaccagggc	7900
acagggcatg	agagctggca	accctccctg	gtgatactgc	cgctgctcag	7950
tctgcagaaa	ctcatcattc	caggctggac	cagactctgg	gccccagggg	8000
cagtgaccag	agccaccttt	ccaggatctg	tcatgctcct	cagggaggaa	8050
gcagtggcca	ctggcagga	tgacagatat	caaggttgtc	actcattgct	8100
gctgttgctc	tgctgtttcc	tccaaccagg	ggcagagccc	tgggggtaag	8150
ggaggggtggc	agccagcagc	ccagccagag	aaggaggagc	cagaggagga	8200
aggctttggt	gtttgttttt	acagggggay	ggtgcagggc	tttaaggagg	8250
tggcttcaag	acctgctgac	tttagccata	aactggtacc	taagggtgct	8300
ggaccctctc	tgtgggatac	atatgcccc	tagtggggat	taagcctgga	8350
gggtggctga	gaaaattaaa	gcaaaacaaa	acaaaaaag	atttactgat	8400
aggctatatg	acctccgaac	ctggatagga	agggccaggg	ctggccccct	8450
gtgtccccga	gattgcacaa	gcacgcacag	gtttaagaca	atgtgcagaa	8500
cccaggtgaa	cgaagcattg	aaagaaatta	tttaatttat	tccttggtca	8550
tttatttaag	aagcatgtat	cgggagcctg	tgatgtacac	acctgtggt	8600
agggttgga	gtcagacagc	aatcaaagg	acggcgcccc	atgtgccaat	8650
gaggacgaca	gaaagatcct	ggccgaggag	gccagttgtg	caagctcagc	8700
cgctgctgct	cacgactttt	acttctctgg	acctcagtct	ccccatgtaa	8750
taggcagtg	tgaacctaa	tgggctggtg	cagaggatgg	gaaggaccac	8800
tgactaccct	ggtaaaatga	aggggatgga	cttcttgacc	tcgggggggg	8850

- continued

cccttccaga	ttcaagacag	gctacagtgg	acagtgtttg	gaggtgctga	8900
caacggtgac	tcgcccactc	agcaagcgtg	tatggagctc	ctgtatgcc	8950
ggcattgtgg	gtggcagaaa	tgaagcrccc	agaaaactgg	acaaaactga	9000
agaagcaaca	gacacttgac	tacaaggaac	atccaagatg	gtgatcccgt	9050
gaccacctca	gcatctacct	cccacaggtc	cctgcctgag	cacaggagg	9100
ggaaaaccag	aggactgcag	tggctctggt	cagctgagga	gacaagatca	9150
gagctcagaa	cagtgtgctg	ttcctaaaga	tatacacaca	catcaatggc	9200
atctccaaaa	cagacacaac	gaagatgatc	caatggagaa	agaaaagccc	9250
ttttgaggaa	acacaaaaag	tgctaaccat	aaaagaaaa	aacagataaa	9300
ttggacttga	tcaaaattct	tggaaagact	ggaagagaat	actagccaag	9350
caaaaatccg	aacaagggcc	tgtatccaaa	atatataaag	aacttttaca	9400
actcaataag	aagacgacag	ccaacggaa	aagtggggga	gggtttta	9450
agacacttgc	caagaaacta	gacatatggc	caataaacac	ataaaaagat	9500
acacaacatc	ctaagccatc	aaggaaatgc	aaattaaaac	cacaatgaga	9550
tactactgca	cactcaccag	aatggataaa	agatggacca	taatagacgt	9600
gggtgaaggt	gtggagcaac	ttgtaaccct	gtcatacggt	gctgggaaac	9650
ctgtttggca	gtttcttagg	atgtaatcca	agaggagtga	acatgtaggt	9700
ccacacaaag	atgtgtacag	agatgttcac	agcagtgtta	ttatcaataa	9750
ttagtatcca	aactggaaac	aacgcagata	gccatcaaga	ggtaaatgga	9800
taaaaaaaa	aaaaaaaaaa	aggagggcgt	gtattcatac	aatggaatac	9850
gattcagcaa	taaaaaggca	ttgagctact	atgtgagcca	taacacaggg	9900
caatgagaga	agccagatgc	taaagagcac	ctacagtatg	aatccattta	9950
taggagattc	tagaacaggc	aataactaat	cgggagtggc	agaaagcaga	10000
tcagtggttg	cccggggcca	gggctggata	tggacactgt	gaaatagcag	10050
gttggtagcc	tccaggggga	tggagatggt	ctaaattgag	actgggggtg	10100
tggttttatg	ggtgtatcac	tggctggact	attttaaatg	gatgcacttt	10150
gttatatgta	aattatacct	caataaagat	gacttaaaga	gttaaaaaaa	10200
aaaaaaaaaa	aaagaaccac	gagaatgaar	acctgatcct	tgtcttgctt	10250
acagtctagt	gaaaacgmca	gatgtgaaaa	caacaacca	taaggcgggtg	10300
agtagcctaa	gaagcatgct	caaataacaa	gagttctggt	tatgaagggc	10350
tcctcgcgc	cagaccaca	gaggtggctt	ggcgtcactg	ttctagaagt	10400
ccagataaga	aaagaggctg	agatggaggg	gaagtgttcc	acgcaggatt	10450
actcagctag	aatcagcagg	cctgggactg	ggctccaagg	ctgcctgggt	10500
tcagagcagg	tgccacagca	gcctgtggca	ggacaccgag	cagagagctc	10550
gggactgttg	cagcttctca	ggtgagactt	tgcggaggag	gtattgacac	10600
aggagtggga	atgtgctcag	cagagtagag	gatgcgggga	aggaaatttc	10650
aaagcaaagg	gaacaaacaa	tatgagcaaa	ggctgggcaa	cacttgtgag	10700
aaggcagggg	tcctgggaat	ggagagacgt	gtcccgaaaa	gagcagaaga	10750
ggtcaacagg	atattacatg	ttcttcgcat	tcacttattt	ttttaagaac	10800
ctattaagca	ataattttta	cgagaggcaa	cagctctgca	gggcaggcaa	10850

-continued

gtgawgtatg tgctcttggc aaacgcaggg aagaaccac cgtgatgcca	10900
aggttgccctc tttagggaaa ggggttctcc ctgtgacatt tctcctctc	10950
caggaggtta aggctgtgtt ccaggatccc aggtttctgc tgaacacct	11000
ttgtggcact ctttcacggt cctgagaaat cccaggagga aaaaaaaaa	11050
aacaaaaacc cgctgtgct tttatgctgg gctttctggc tggaggaagt	11100
caagtcaactg gagcgaagca aatgtgtca cactgtcatg gtgcgttctt	11150
ctggaaactc agcacagcag tgaggtttgg aggctttgag gctggactgg	11200
ctgaggtcag atctcagcgc tctttcacac tgattacttt cccctttctg	11250
cactttggct tctttagaag attgcaaaag aggggtgatc ataagagggc	11300
agatgtgaga atgaagggac agtacgtgca atgtgtcag tcagactcat	11350
cgagtctgag acgttaattt agcctgtata gccttttgta tgacagtcag	11400
tctccataa atcagttttt taaaaagaag gtgcttagag cagagcctgg	11450
cccagagcaa acatttaata gacagtagct tttgtgtttt caaaaaggtg	11500
acatgcacat gtcacccctt ttattttgct gtgaccggt ctttcagaga	11550
attataatga agcgggattt gggacatggt gatcatatca tttaggatga	11600
ttgtgactct taacagaaca cccaacttag ggtggctcaa acaggaagga	11650
gatttctaaa tctcacattc tggggcgctt ggggtggcaca gttggttaaa	11700
cattcgactc ttggttttgg ctcaggtcag gatctcaggg ttgtgagatg	11750
gggccctgtg ttggagtctg cgctcagctc acaattctct ctctcctcca	11800
cttctgcccc tctgcccctc tctaaaataa acatttgagg gtttttttaa	11850
aaagatttta tttagttagt tgagagagag acagacagag acagagagac	11900
agagagtgag catgtgtgag cacaggtggg gaagggcaga gggagcagca	11950
gaatccctgc tgagcaggaa gcccaacaca ggccttgatc ccaggacca	12000
gatcaagacc cgagccaaag gcagatgctc atccaactga gccagccagg	12050
caaccctaaa ataatgtct ttttttaaaa aatcatcctg tgtttcactg	12100
aaactaacat gccattgctt gtgagatgcc ccttgcatc agaaatatta	12150
aaatataaaa atgtgtgtct ttgarttgaa acaaaaggtc tgaaggtagg	12200
gggctctagg actggttaatt tggcagttca ccatgaggac tctttgtcct	12250
ttgtttccac tctgccatcg tcagacctta ggctctggct ttgaggcaag	12300
cctcatggat gcaagatggc tgccagggcc tcaagcatca agtcttcaga	12350
gcctccaaa gccagaagag aggctgctgt ttttaaaaac aagaaaact	12400
ttccaaaact ttgcttaatt gcatcaciaa ccctttctg aattcctggc	12450
agaaggaata gatttatcat aagggtctgg tgccgactct tcaagattcg	12500
cccttagggc cggggaggag cttgcctcca ctgaagcacc gagctccagt	12550
tctgttgatg gatggaggaa gaacagctgt gagctggcaa tgagcagcgc	12600
tgccatacag atraaccgcc tgtgaatcac cggccaactg tgcccagacg	12650
aagcagctga ctgcttggga tattcctacc caccttctg ttcctatcaa	12700
caatggtaga gcttctctc caggtaaga aattaacctc catattccaa	12750
agacttggtt tcctattaat gtggctttcg ggtaccgat ccaaatcct	12800

- continued

atccggatgg aaccagtgga gttagccacc tgagcacagc aggccaatgg	12850
actagatttc acctccgtgc tcagagccaa ggccccctga cgcaccgag	12900
gactgtggcc ttgctcagcc tgggatctac ttctgtcact gaccactaga	12950
ttgggggact ccgtgtcagt gaatacagat ccatgctagc ctaggatgac	13000
ggctacgtaa caattccact gcacataaaa actcaagtgt cccagacctc	13050
ggggcgctg gctggcttag ggaggactga ctcttaatct cagagtcttg	13100
agttcaagcc ctgtgttggg tgtggagcct acttaaaaaa aaaaagaaga	13150
agaagaagaa ggagaaggag aaggagaagg agaaggagaa ggagaaggag	13200
aaggagaaga agaagaagaa gaagaagaag aagaagaaga agaagaagaa	13250
gaaagaagaa gaagaagaag aagaagaatt agaaatcaca acattgatgc	13300
tttgatctcc acagctctga actcccgcct gtccttcag aaatctgatg	13350
cgttctctgt tgtctttcca ctgatttttt tctttttttt ttaagatttt	13400
atattttga cacacagaga gatcagcagg gggagcatca gagggagagg	13450
gagcagcagg ctccccgctg agcaggaagt ccaacatggg gctcaatccc	13500
aggacctgg gatcatgacc tcagccaaag gcagatgttt aaccactga	13550
gccaccagg tggccctgat ttttttttta agattattta tttattttag	13600
ggatccctgg gtggcgagc ggtttaccgc ctgcctttgg cccagggcgc	13650
aatcctggag acctgggatc gagtgccaca tcgggctccc ggtgcatggg	13700
gctgcttct cctctgcct atgtttctgc ctctctctct ctctctgtgt	13750
gactacaata aattaataaa tattttttaa tattatttat ttattttaaa	13800
atattttatt tatttattca tgagagacac agagagagag gcagagatac	13850
aggcagaggg agaagtaggc tcccacagga cttgatccca ggacctcagg	13900
atcacgacct gaatccaagg cagatgctca accactgagc caccaggtg	13950
tcccattaaa gattatttat ttgacagaga gagagagagc aggagcagag	14000
gggcacaggg agaagaagac ttctgctga tcgaggagcc cgacatgggg	14050
cttgaaccta gaacctaaag atcatgacct aagtgaagg cagatgctta	14100
accaatggag ccaccaggtg cccatcctc ccctatttct ggactgcca	14150
ggcagtgtgc cctctgctg ccaactcttc tgettgtgtg ctctattttt	14200
caaataaata aattaataa aaaataataa tcttgaggca cctgggtggc	14250
tcagtggttg aacatctgtc tttggctcag ggcgtgatcc tggggctctg	14300
ggatcgagtc ccacattggg ctccctggat ggagactgct tctctctctg	14350
cctgtgtctc tgctctctc tctctgtgtg tgtgtgtctc tcatgaataa	14400
ataataaaaa gggatccctg ggtggcacag tggtttagcg cctgcctttg	14450
gccagggcg cgatcctgga gacctgggat cgaatcccac gtcgggctcc	14500
cggatgatgg agcctgctc tccctctgcc tatgtctggg atccctgggt	14550
ggcacagcgg tttggtgctt gcctttgggc cagggcgtga tcctggagac	14600
ccgggatcga atcccacatc gggtccccg tgcatggagc ctgcttctcc	14650
ttctgcctgt gtctctgct ctctctctct ctgtgtgact atcatgaata	14700
aataaataaa atcttaaaaa aaaaataaat aaataaaatc tttttattag	14750
atattattta aatcttttta ttagatttta atctcactgc gttttgctcc	14800

- continued

ggcctctcgg	cgctgcca	gccacccgag	acatgccacc	tgcggtgaac	14850
ctgctgctct	tctactaggt	gtcctgtcag	gtgtgaaagc	tccactgtag	14900
accgtggcat	tgtggctcct	ctcaagccca	gaagaatgct	ccatgctcct	14950
cacacgcact	agctggcaac	cggctctggga	ctcaagacag	ccctgctaga	15000
gcccagagcc	ccccagtctt	gcagccatca	gycctgcag	cctctcctcc	15050
tcactctgct	tgccataaag	tggctcaaaa	ccacggaaca	ggtgcccac	15100
attcccctga	gtaatttcat	cccaaccacc	cctgcaaaca	cacaaaacct	15150
ttctttgctc	ctctcccca	tgccccaaaag	ccctatagta	agactgatgt	15200
atagatatac	gaagttcagt	acatcttagt	ggtgagagta	tggactctgc	15250
aggctggcct	caaaccttga	ccccagcaat	cactagttgt	gtgaatttgg	15300
gaaagtcacc	tcactctca	ctcacctcac	ctcatctgcg	aaatgcrngt	15350
agtgatagwg	cccttcagag	ggcagcgggtg	cacattaaac	aaattggtgt	15400
gcgttcagta	ctccaggagt	ggacggcgca	tggtaagtgc	taccyggat	15450
ccactctcgc	tgttatcgg	cctgcagegg	gtcccttgcc	tccatccaag	15500
cagctctggg	gaacttccac	attcaaaact	ccctctccga	gtctgaaaat	15550
gaaaggaact	tagttttcag	ggagagagcc	cattcctcct	ttccctattc	15600
tacaaaactg	tattcaaggg	caagacagaa	atgcaagggc	cagtttcata	15650
agacagatgt	tactgccaag	tgagtcaatg	attatctggt	gtgtacgtgg	15700
gcagaggcag	aggaataaca	accagactct	gggaggcaat	taaaaagaaa	15750
aaaaaaaaaa	gtaaaagagt	gtctcatgga	gcgcctgggt	ggctcagtcc	15800
gttaagcctt	ggacttttgg	tttcccctca	ggtcatgac	tcagggtcgt	15850
gggaccagc	cctggggcgg	gctctgtgat	cagtggggag	cctgcttgag	15900
attcccctct	tctgctgtgc	acactctctc	tctaaaataa	atacgtcttt	15950
agaagagcaa	gcgagcgaga	gatgcttccc	gcctagaaga	gcttacaatc	16000
aatcaaggg	aggcaaacat	aaacaagtgt	ggcaacttga	taataagcac	16050
ctgcgacct	tggccataca	cagaataaca	taaccagac	taaatgccac	16100
tgcatagtca	ctagcgggtt	gatgacaacg	ggggaggct	aatgctgaaa	16150
aggcctttct	gtcttataag	tttaactaa	tttctggggg	cacctgggtg	16200
gctctgggtg	agcatctgcc	tttgggtcgt	cgcccagggt	tcctgagatc	16250
gagtcccctca	tccggctccc	agcccctag	gagcctgctt	ctcccctctgc	16300
ctcttccctct	ctgtctctca	tgaataaata	aataaaaatt	ttaagggatg	16350
cccgggtggc	tcagcgggtt	agcgcctgcc	tttggcccag	ggtgtgatcc	16400
tgggtccc	agatcgagtc	ccacatcgag	tcccacatcg	agttccggga	16450
tcgagtcct	gcaggaacc	tgttctccc	tctcccctgtg	tgtgtgtctc	16500
tctctctttc	tgtatctctc	atgaataaat	aaagaaaatc	tttaaaaata	16550
aataaataaa	aacagtat	aaaaaatga	actaatttcc	aagtaggtgt	16600
aaattctggc	tccgactagt	gaatggctct	ggctctgctg	catcaccac	16650
cgccagggtc	ctgggccgct	ccgagccccg	ctcgcggcg	ccccctgccg	16700
cccgggctc	ccgccttca	cccaaccgc	agggcggcg	agccctaggc	16750

-continued

```

ccaatcgccc cggggaacct gccgcctctt ctctagcgca acccagcacc      16800
cagatgaccc cttttccgcc ccaggtgcag tccggccggg ccctggtgtc      16850
ctcaccogtt cccctagggg gacccctctc gaaccttctg cgccacccta      16900
ctctacgcca gggaaaatct gtgcactcag tagataaatg cttgtaactg      16950
aagcaaccgt ctccgtggct ccagaatcgc gctgaggatg ctgctgccgc      17000
acccccacct ccccggtctc cggcggagggt tgtttggact acacttccca      17050
tgaggccctt ctcaacatcg cgataactct cgcgagaccg ctgggaagag      17100
ttgtgcgcag ggcagcccc gccttcttgt cgaggcagge cgcgtggccg      17150
gcagtcatgg cggctccttg ctggcccgc cgggacaggg agtctggagy      17200
ctctggctgt ggtaagggtg tcgaggcggg cagacgggat cgtccttggc      17250
ccggcgctag ttcgctcggc ctccctttcc tcggggggcg gatgatgacg      17300
gtaaagccgg tcttctcgt aggggtggtt ggttagttga gatgctggat      17350
cggaaaacgc tttctgagcg gcgcgagtgt tgacgatcga agggagagag      17400
ctcagcccc ccttgagtc agagggcccc tctgggggg gggggtcctc      17450
cagcctgtgc agccccgtgt gtgcctcgc ggtctcccg gcccgccac      17500
gggaggctgc cgggtgtagt tcttaatcca catcaagtgt taacgtgagg      17550
gtcctggagt gccccgaggt cggccctggt cagtggttcg tattcagtc      17600
tacagatagt agtaaaggg cttgtagatt ttggaaagcc ataatgctct      17650
gcgccctacc ttccatgtc atttttttc cctctctct tcccgtagag      17700
ggttttcttt gcgtcgaga cctgcagggt gaagcttaa agtagcgaat      17750
ggggagccct gtgaaatgg taaggatggg tgctggcagg gcccggtgg      17800
tgaccagaag tgagaaagtc gagatggtgg gcaggcctgc cacaccggc      17850
cgccgcacgc tttactttac taattttatt tttttttaa grtttaatta      17900
attaattaat taatgatagg cagagacaca ggcagaggga gaagcaggct      17950
ccgtgcgggg agcccgacgc gggactccag gatcgcgccc tgggccaaag      18000
gcaggcgcca aaccgctgag ccaccaggg atcccacttt accgatttta      18050
agttcggttc ttaggaacac gtggacgcac gcatccggtt agggtgagaa      18100
gaaaaaggac cggggtcctg gaagcgagca gggccttgc agtgtgactc      18150
ggcgcgcta ggtgtcactg tttggattca aaccggttc cgcgcacgag      18200
gttggcgggg aggcttagga aatgggcttc ggtggggtt ggaagtatt      18250
gtggatgatt taaagttatc tttgtcttaa agggctcttt tgtgaagagt      18300
tttgatgcgt tgaggctcag ctttttttt ttttttttt taaggtttgt      18350
attcattttt tcacagagag gcagagggag gagaagcttg ctgcctgcag      18400
agagcaggat gcgagactcg atccctggat ttcgggatca cgccagagc      18450
caaaggcaga cacgcaacta ctgagccacc caggcgtccc gaggccccag      18500
cttcttaaat aaccaatctt gagaataaca tcttgacctc atttctctta      18550
gaatatactt tgttacattt cccttagaga ttaaagggtg tg      18592

```

<210> SEQ ID NO 2

<211> LENGTH: 54

<212> TYPE: PRT

<213> ORGANISM: canis familiaris

-continued

<400> SEQUENCE: 2

Met Cys Thr Thr Leu Phe Leu Leu Ser Thr Leu Ala
5 10Met Leu Trp Arg Arg Arg Phe Ala Asn Arg Val Gln
15 20Pro Glu Pro Ser Gly Ala Asp Gly Ala Val Val Gly
25 30 35Ser Arg Ser Glu Arg Asp Leu Gln Ser Ser Gly Arg
40 45Lys Glu Glu Pro Leu Lys
50

<210> SEQ ID NO 3

<211> LENGTH: 695

<212> TYPE: DNA

<213> ORGANISM: canis familiaris

<400> SEQUENCE: 3

```

agtggcagca ggaacctcag gatgggcagc agtggcttgt gagagccggc      50
agggccattt tggcctttct cctgcagact ctgtccggga ggggatgggg      100
cagctgagcc atgtrcacca ccctcttctt actcagcacc ttggccatgc      150
tctggcgccg ccggttcgcc aaccgggtcc aaccggagcc cagcggagca      200
gacggggcag tcgtgggcag caggtcggag agagacctcc agtcctcggg      250
cagaaaggaa gagcctctga agtaagtctt cacccgggta ggccggagctc      300
ggccccaggg aytgggatca gctggcagag gcagttcaag tcccggctgg      350
cctcttacc ccaaagcatg ctgtgggtga agcagcagca gcagcaagaa      400
gaaaaatggg aaaaagcagt catcaagaag gtagactcct ccctttgagt      450
ccctggacct gcctggcctc cctttgcccc agaccctggg ggtggggctc      500
ctgaagcaag gcctggctgg ggcaggctgg agggcaaaga cgctcattgc      550
cctggcttgg gctcccttcc tctgagatcc tgaggatagt ctgaggcagg      600
cccagagagg gactcaggtt ttttatggaa ggretttctca ttcateccta      650
atataatcct tgcaatgacc caaaaaaaaa aaaaaaaaaa aaaaaa      695

```

<210> SEQ ID NO 4

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: RT-PCR forward primer

<400> SEQUENCE: 4

caccttgccc atgctctggc 20

<210> SEQ ID NO 5

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: RT-PCR reverse primer

<400> SEQUENCE: 5

aatgcatata aataagcac ttggc 25

-continued

<210> SEQ ID NO 6
 <211> LENGTH: 18
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT-PCR forward primer

 <400> SEQUENCE: 6

 ccagtggcag caggaacc 18

<210> SEQ ID NO 7
 <211> LENGTH: 18
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT-PCR reverse primer

 <400> SEQUENCE: 7

 ccaagccagg gcatgagc 18

<210> SEQ ID NO 8
 <211> LENGTH: 29
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: reverse primer located on exon 1

 <400> SEQUENCE: 8

 ccaaggtgct gagtaggaag aggggtggtg 29

<210> SEQ ID NO 9
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: reverse primer located on exon 3

 <400> SEQUENCE: 9

 agtccctggg gccgagctcc gcctgac 27

<210> SEQ ID NO 10
 <211> LENGTH: 29
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: forward primer located on exon 1

 <400> SEQUENCE: 10

 caccaccctc ttcctactca gcaccttg 29

<210> SEQ ID NO 11
 <211> LENGTH: 28
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: forward primer located on exon 3

 <400> SEQUENCE: 11

 agggactggg atcagctggc agaggcag 28

<210> SEQ ID NO 12
 <211> LENGTH: 1084
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: EST clone contig

-continued

<400> SEQUENCE: 12

gagcagctgc agcagctgcc actgccctgt gtcaccccag ggtgcaaag	50
ccaccacggg gagcaccccg cccatcccga actgtgtggc tgtgcagatg	100
cgggcaggat ggtcctgggc acaggccttg gtccaagacc aggcaggcgt	150
ggtacttgat ctgaggtggg catcatggca caggagctgg tcccaggggt	200
gcccggggac ctttatagaa cctcagtcgg gaagaagccc aagacctga	250
gccagagggga agtaatgctt ctttgtgagc ctcaaagga gggaaatggc	300
caaggtttac agtaataaa tgacactaat attattatta ataatggcta	350
atgtgtctca aacgcttctt acgtgctagg cgctgtgcca agtgctttat	400
ttatatgcat tgtctcattt atggggcagg aactggtgtc agtctcattt	450
accaataag gaaagtgctt gctcaaggtc acccacagtg agtagtgaag	500
ccaggacgtg tccccggca aggtgatgta aaagcctgtg aaggatttg	550
gcctcgagga catcctggga gtgtgacctg tccaccaggc cacagggcat	600
gagagctggc aaccctccct ggtgatactg ccgtgctca gtctgcagaa	650
actcatcatt ccaggctgga ccagactctg ggccccgagg gcagtgacca	700
gagccacctt tccaggatct gtcagtctcc tcaggaggga agcagtggcc	750
actggcaggg atgacagata tcaaggttgt cactcattgc tgctgttget	800
ctgctgtttc ctccaaccag gggcagagcc ctgggggtaa gggagggtgg	850
cagccagcag cccagccaga gaaggaggag ccagaggagg aaggctttgt	900
tgtttgtttt tacaggggga cgggtgcaggg ctttaaggag gtggcttcaa	950
gacctgctga ctttagccat aaactggtac ctaagggtgc tggaccctct	1000
ctgtgggata catatgcccc ctagtgggga ttaagcctgg aggggtggctg	1050
agaaattaa gcaaaaaaaaa aaaaaaaaaa aaaa	1084

<210> SEQ ID NO 13

<211> LENGTH: 707

<212> TYPE: DNA

<213> ORGANISM: artificial sequence

<220> FEATURE:

<221> NAME/KEY: unsure

<222> LOCATION: 598, 602

<223> OTHER INFORMATION: Clone 9 sequence; RT-PCR product; n is g, a, t
or c

<400> SEQUENCE: 13

caccttgccc atgctctggc gccgcccgtt cgccaaccgg gtccaaccgg	50
agcccagcgg agcagacggg gcagtcgtgg gcagcaggtc ggagagagac	100
ctccagtcct cgggcagaaa ggaagagcct ctgaagtaag tcttcaccgg	150
gtcaggcggg gctcggcccc agggactggg atcagctggc agaggcagtt	200
caagtcccgg ctggcctctt acccaciaag catgctgtgg tggagcagc	250
agcagcagca agaagaaaaa tgggaaaaag cagtcatcaa gaaggtagac	300
tctcccttt gagtccttgg acctgcctgg cctccctttg ccccagacc	350
tggtgggtgg gctcctgaag caaggcctgg ctggggcagg ctggagggca	400
aagacgctca ttgccttggc ttgggctccc ttctctgag atcctgagga	450
tagtctgagg caggcccaga gagggactca ggtttcttat ggaaggrett	500

-continued

```

ctcattcattc cctaataataa tccttgcaat gacccaaga ccttgagcca      550
gaggaagta atgcttcttt gtgagcctca aaaggaggga aatggccnag      600
gnttacagta atataatgac actaatatta ttattaataa tggctaattgt      650
gtctcaaacg cttcttacgt gctagggcgt gtgccaagtg ctttatttat      700
atgcatt                                                         707

```

```

<210> SEQ ID NO 14
<211> LENGTH: 562
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR exons 1-4

```

<400> SEQUENCE: 14

```

ccagtggcag caggaacctc aggatgggca gcagtggctt gtgagagccg      50
gcagggccat tttggccttt ctctgcaga ctctgtccgg gaggggatgg      100
ggcagctgag ccatgtrcac caccctcttc ctactcagca ccttggccat      150
gctctggcgc cgccggttcg ccaaccgggt ccaaccggag cccagcggag      200
cagacggggc agtcgtgggc agcaggtcgg agagagacct ccagtcctcg      250
ggcagaaagg aagagcctct gaagtaagtc ttcaccgggt caggcggagc      300
tcggccccag ggactgggat cagctggcag aggcagttca agtcccggct      350
ggcctcttac ccacaaagca tgctgtggtg gaagcagcag cagcagcaag      400
aagaaaaatg ggaaaaagca gtcatacaaga aggtagactc ctccctttga      450
gtccctggac ctgcctggcc tccctttgcc ccagaccctg gtggtggggc      500
tcctgaagca aggcctggct ggggcaggct ggagggcaaaa gacgctcatt      550
gccctggctt gg                                                         562

```

```

<210> SEQ ID NO 15
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR forward primer from exon 3

```

<400> SEQUENCE: 15

```

cagtcgtggg cagcaggtcg g                                                         21

```

```

<210> SEQ ID NO 16
<211> LENGTH: 25
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR reverse primer from exon 8

```

<400> SEQUENCE: 16

```

aatgcatata aataaagcac ttggc                                                         25

```

```

<210> SEQ ID NO 17
<211> LENGTH: 316
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR product

```

<400> SEQUENCE: 17

```

cagtcgtggg cagcaggtcg gagagagacc tccagtcctc gggcagaaag      50

```

-continued

```

gaagagcctc tgaagtaagt cttcaccggt tcaggcggag ctcggeccca      100
ggggtgcccg gggaccttta tagaacctca gtcgggaaga agcccaagac      150
cttgagccag agggaagtaa tgcttctttg tgagcctcaa aaggaggaa      200
atggccaagg tttacagtaa tataatgaca ctaatattat tattaataat      250
ggctaattgt tctcaaacgc ttcttacgtg ctaggcgtg tgccaagtgc      300
tttatttata tgcatt                                             316

```

```

<210> SEQ ID NO 18
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR forward primer from exon 2

```

```

<400> SEQUENCE: 18

```

```

gcagcaggtc ggagagagac                                             20

```

```

<210> SEQ ID NO 19
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR reverse primer from exon 5

```

```

<400> SEQUENCE: 19

```

```

cttcctcag atgtggagtc ag                                             22

```

```

<210> SEQ ID NO 20
<211> LENGTH: 796
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR product no. 1

```

```

<400> SEQUENCE: 20

```

```

gccaccgggt ccaccggagc ccagcggagc agacggggca gtcgtgggca      50
gcaggtcgga gagagacctc cagtcctcgg gcagaaagga agagcctctg     100
aagtaagtct tcaccgggtc aggcggagct cggccccagg gactgggatc     150
agctggcaga ggcagttcaa gtcccggctg gcctcttacc caciaagcat     200
gctgtggtgg aagcagcagc agcagcaaga agaaaaatgg gaaaaagcag     250
tcatcaagaa gtttccaggg cacttgcttc tccccggtec ccagagctca     300
ccccgtcacc agccactctg ctgcagttct caataagaaa tgccagctgg     350
gatctgtgac atgtctgcct ggggctggaa ggaagcatct ctcaacctgt     400
cctctgagcg tgtctgcgtg cctgtgtgca tgcgtgcgtg tgttccaaag     450
gggcagtcgc atgtgggaag ggaagaagcc tgacacttgt tcttgtcaat     500
ctgctgactg ctcagtagca cggcggtctt gccatttctc cctcacagtc     550
ctgctcgacc cagagcagag atcaaagcag atttccgctt ctgctccctg     600
agatccaggc gcagacctgc aggcagctgc tccccactgt ctggaagcca     650
ttcatcatgc aaagcgcctc cccaccaaac ccctgcctgc acgtgcatcg     700
tccccccacc atcaccatcc agccccagg gtgggcaggg aggtccctgc     750
ctagctgcac accccccagg ccatcaagag gcaggagatg gggagt          796

```

-continued

```

<210> SEQ ID NO 21
<211> LENGTH: 763
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR product no. 2

<400> SEQUENCE: 21
gccaccgggt ccaccggagc ccagcgggagc agacggggca gtcgtgggca      50
gcaggtcggg gagagacctc cagtcctcgg gcagaaagga agagcctctg      100
aagtaagtct tcaccgggtc aggcgggagct cggccccagg gactgggatc      150
agctggcaga ggcagttcaa gtcccggctg gcctcttacc caciaagcat      200
gctgtggtgg aagcagcagc agcagcaaga agaaaaatgg gaaaaagcag      250
tcatcaagaa gagctcacc cgtcaccagc cactctgctg cagttctcaa      300
taagaaatgc cagctgggat ctgtgacatg tctgcctgcg gctggaagga      350
agcatctctc aacctgtcct ctgagcgtgt ctgctgcct gtgtgcatgc      400
gtgctgtgtg tccaaagggg cagtcgcatg tgggaagggg agaagcctga      450
cacttgttct tgtcaatctg ctgactgctc agtaccacgg cggctctgcc      500
atttctccct cacagtcctg ctgacccagc agcagagatc aaagcagatt      550
tccgcttctg ctccctgaga tccaggcgca gacctgcagg cagctgctcc      600
ccactgtctg gaagccattc atcatgcaaa gcgcctcccc accaaacccc      650
tgctgcacg  tgcctgctc cccaccatc accatccagc ccccagggtg      700
ggcagggagg tccctgccta gctgcacacc ccccaggcca tcaagaggca      750
ggagatgggg agt                                             763

```

```

<210> SEQ ID NO 22
<211> LENGTH: 509
<212> TYPE: DNA
<213> ORGANISM: artificial sequence
<220> FEATURE:
<223> OTHER INFORMATION: RT-PCR product no. 3

<400> SEQUENCE: 22
gccaccgggt ccaccggagc ccagcgggagc agacggggca gtcgtgggca      50
gcaggtcggg gagagacctc cagtcctcgg gcagaaagga agagcctctg      100
aagtaagtct tcaccgggtc aggcgggagct cggccccagg gactgggatc      150
agctggcaga ggcagttcaa gtcccggctg gcctcttacc caciaagcat      200
gctgtggtgg aagcagcagc agcagcaaga agaaaaatgg gaaaaagcag      250
tcatcaagaa gtctgctcg acccagagca gagatcaaag cagatttccg      300
cttctgctcc ctgagatcca ggccgagacc tgcaggcagc tgctccccac      350
tgtctggaag ccattcatca tgcaaagcgc ctccccacca aaccctgcc      400
tgcaagtgca tegtcccccc accatcacca tccagcccc aggggtgggca      450
gggaggtccc tgcttagctg cacaccccc aggccatcaa gaggcaggag      500
atggggaggt                                             509

```

```

<210> SEQ ID NO 23
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: artificial sequence

```

-continued

<220> FEATURE:
 <223> OTHER INFORMATION: Pyrosequencing forward primer

<400> SEQUENCE: 23

ttgtgagagc cggcagg 17

<210> SEQ ID NO 24
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Pyrosequencing biotin labeled reverse primer

<400> SEQUENCE: 24

atggccaagg tgctgagtag 20

<210> SEQ ID NO 25
 <211> LENGTH: 15
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Pyrosequencing oligo probe

<400> SEQUENCE: 25

ggggcagctg agcca 15

<210> SEQ ID NO 26
 <211> LENGTH: 113
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Pyrosequencing PCR product

<400> SEQUENCE: 26

ttgtgagagc cggcaggggc cattttggcc tttctcctgc agactctgtc 50

cgggagggga tggggcagct gagccatgtr caccaccctc ttctactca 100

gcaccttgge cat 113

<210> SEQ ID NO 27
 <211> LENGTH: 18
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: forward primer

<400> SEQUENCE: 27

ccagtggcag caggaacc 18

<210> SEQ ID NO 28
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: reverse primer

<400> SEQUENCE: 28

ccgacctgct gccacgact g 21

<210> SEQ ID NO 29
 <211> LENGTH: 21
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT-PCR forward primer

-continued

<400> SEQUENCE: 29

agtggcagca ggaacctcag g 21

<210> SEQ ID NO 30
 <211> LENGTH: 26
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT-PCR reverse primer

<400> SEQUENCE: 30

ggattatatt agggatgaat gagaag 26

<210> SEQ ID NO 31
 <211> LENGTH: 22
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT-PCR forward primer

<400> SEQUENCE: 31

ttaatcagtc tgcacaaggt cg 22

<210> SEQ ID NO 32
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: RT-PCR reverse primer
 <220> FEATURE:
 <223> OTHER INFORMATION: amplification primer

<400> SEQUENCE: 32

gggtcattgc aaggattata ttagg 25

<210> SEQ ID NO 33
 <211> LENGTH: 1015
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT-PCR splice variant product no. 1

<400> SEQUENCE: 33

ttaatcagtc tgcacaaggt cgggttggt gacccccacta atcagcttga 50

gcctcctaat ccagtggcag caggaacctc aggatgggca gcagtggctt 100

gtgagagccg gcagggccat tttggccttt ctctgcaga ctctgtccgg 150

gaggggatgg ggcagctgag ccatgtrcac caccctcttc ctactcagca 200

ccttggccat gctctggcgc cgccgggttcg ccaaccgggt ccaaccgtga 250

gaagctgatg gggccatggg cagggatggg gagagaggag aagctagggg 300

gtgaggggtg gtgcaggggc tgccctggacc tcctgggagg ctggagggcg 350

gggaggattt gcagggaggt ccagagaggt ttcccatcag agcacgcggg 400

ggcgggggct cgcaggtgct ccgagactgg ctggagtccc cggccccca 450

gccccaacag gccaggagag ggggttcttg gcccgggcgc tgccccacagc 500

tcttcagcc tcttcctccc gccacaggg agcccagcgg agcagacggg 550

gcagtcgtgg gcagcaggtc ggagagagac ctccagtcct cgggcagaaa 600

ggaagagcct ctgaagtaag tcttcacccg gtcaggcggg gctcggcccc 650

agggactggg atcagctggc agaggcagtt caagtcccgg ctggcctctt 700

accacaaaag catgctgtgg tggaagcagc agcagcagca agaagaaaa 750

-continued

tgggaaaaag cagtcacaa gaaggtagac tctcccttt gagtcctgg	800
acctgcctgg cctccctttg cccagaccc tgggtggtggg gctcctgaag	850
caaggcctgg ctggggcagg ctggagggca aagacgctca ttgcctggc	900
ttgggctccc ttctctgag atcctgagga tagtctgagg caggcccaga	950
gagggactca ggtttcttat ggaagggtt ctcatcctc cctaataata	1000
tccttgcaat gaccc	1015

<210> SEQ ID NO 34
 <211> LENGTH: 733
 <212> TYPE: DNA
 <213> ORGANISM: artificial sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: RT-PCR splice variant product no. 2

<400> SEQUENCE: 34

ttaatcagtc tgcacaaggt cgggttggt gaccccaacta atcagcttga	50
gcctcctaat ccagtggcag caggaacctc aggatgggca gcagtggctt	100
gtgagagccg gcagggccat tttggccttt ctctgcaga ctctgtccgg	150
gaggggatgg ggcagctgag ccattgtrac caccctcttc ctactcagca	200
ccttgccat gctctgggc cgccgggttcg ccaaccgggt ccaaccggag	250
cccagcggag cagacggggc agtcgtgggc agcaggtcgg agagagacct	300
ccagtctcgg ggcagaaagg aagagcctct gaagtaagtc ttcaccgggt	350
caggcggagc tgggcccag ggactgggat cagctggcag aggcagttca	400
agtcccggct ggcctcttac ccacaaagca tgctgtggtg gaagcagcag	450
cagcagcaag aagaaaaatg ggaaaaagca gtcatcaaga aggtagactc	500
ctccctttga gtcctggac ctgectggcc tcctttgccc ccagaccctg	550
gtggtggggc tctgaagca aggcctggct ggggcaggct ggagggcaaa	600
gacgtcatt gccctggctt gggctccctt cctctgagat cctgaggata	650
gtctgaggca ggcccagaga gggactcagg tttcttatgg aagggttct	700
cattcatccc taatataatc cttgcaatga ccc	733

The invention claimed is:

1. An isolated polynucleotide comprising a DNA sequence of SEQ ID NO:1, a RNA sequence corresponding to SEQ ID NO:1, the DNA sequence complementary to SEQ ID NO:1 or the RNA sequence complementary to SEQ ID NO:1.

2. An isolated polynucleotide comprising a DNA sequence of SEQ ID NO:3, a RNA sequence corresponding to SEQ ID NO:3, the DNA sequence complementary to SEQ ID NO:3 or the RNA sequence complementary to SEQ ID NO:3.

* * * * *